

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855
Article Type:	Research
Date Submitted by the Author:	21-May-2015
Complete List of Authors:	Liu, Lei Wu, Jingyang Geng, Jin Yuan, Zhe Lian, Jie; ophthalmology Chen, Lei Teng, Weiping Huang, Desheng; School of Public Health, China Medical University., Epidemiology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

only

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Jingyang Wu^{#1}, Jin Geng¹, Zhe Yuan¹, Jie Lian², Lei Chen^{1,3*}, Weiping Teng³, Desheng Huang^{4*}

Authors' illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3
4 Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,

5
6 P.R. China 110001

7
8
9 Tel: +86-13889378662 Fax:+86-24-83283590

10
11 E-mail: huangdsll@163.com

12
13
14 **Prof. Lei Chen**

15
16 Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,

17
18 P.R. China 110122

19
20
21 Tel: +86-13889378662 Fax:+86-24-83282630

22
23
24 E-mail: carol1422@163.com

ABSTRACT

PURPOSE. To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

METHODS. A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District. All participants underwent a standardized interview and extensive examination.

RESULTS. The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

CONCLUSIONS. The presence of MS and its components are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It is unclear whether the MS is associated with retinopathy in North Chinese population. We examined the cross-sectional association of the MS and retinopathy in this population-based study.

METHODS

Study population

There were more than 80,000 residents and five communities (including Yutan, Yonghuan, Taoyuan, Qingnian and Zhongxin community) in Fengyutan Sub-District, Shenyang, North China. Firstly, four communities were randomly selected from five communities in Fengyutan Sub-District. Secondly, 400 households in each of four selected communities were randomly chosen. The participants had lived in Fengyutan for at least two years at the time the research was conducted. Then the selected

1
2
3 households were informed by community officers using message or telephone call.
4
5
6 Finally, a total of 1400 subjects, aged over 40 years were randomly recruited from
7
8 August 2013 to September 2014. After excluding the patients with cancer, hepatic
9
10 failure, renal failure, severe psychiatric disturbance, any other systemic medical
11
12 condition e.g. severe cardiac impairment or severe respiratory impairment, and
13
14 subjects who did not want to attend this study voluntarily, a total of 1163 (response
15
16 rate 83.07%) eligible participants attended this research.
17
18
19

20 21 **Data collection**

22
23 Information on age, smoking, drinking, and health status was obtained using a
24
25 standardized questionnaire. In addition, participants were asked whether they suffer
26
27 from DM and if the diagnosis was made by a physician. All subjects were also asked
28
29 to provide information on their current medication. Thus, known diabetes was defined
30
31 according to self-reported physician diagnosis or the use of anti-diabetic agents.
32
33 Following a community office worker interview, all participants were asked to fast
34
35 overnight (>8 hours) before a physical examination. Waist circumference was
36
37 measured at the level of the umbilicus in the standing position. Height and weight
38
39 were measured without wearing hats or heavy coats. Blood pressure (BP) was
40
41 measured in the sitting position (first) and supine position (second) at a 5-min interval
42
43 using an upright standard sphygmomanometer. Vigorous physical activity and
44
45 smoking were avoided for at least 30 min before BP measurement. The second BP
46
47 measurement with the fifth phase diastolic pressure was used for analysis. All the
48
49 participants were took the stereo fundus photography to detect retinopathy by 45°
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Non-Mydriatic Fundus Camera (CR6-45NM, Canon, Tokyo, Japan) through undilated
5
6 pupils. For each subject, two images for each eye centered on the fovea and optic disk
7
8 were taken in the physiologically within a darkened room. Each image was graded in
9
10 a masked manner by two well-trained ophthalmologists separately for the presence of
11
12 retinopathy lesions. If the grades were inconsistent, the other ophthalmologist would
13
14 give the final diagnosis. The grade of retinopathy for each eye was determined and the
15
16 individual classification was based upon the worse eye. There were 41 subjects that
17
18 could not get a clear retinal image because anterior segment opacity. They accepted
19
20 mydriasis with tropicamide 1% (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before
21
22 20 minutes of dark adaptation and binocular indirect ophthalmoscope by two
23
24 ophthalmologists who reviewed retinal images.
25
26
27
28
29

30
31 The mayor and the welfare section of Fengyutan Sub-District approved this study. The
32
33 research followed the tenets of the Declaration of Helsinki and informed consent was
34
35 obtained from the subjects after explanation of the nature and possible consequences
36
37 of the study and the research was approved by Institutional Ethics Committee of The
38
39 First Affiliated Hospital of China Medical University.
40
41
42

43 44 **Laboratory methods**

45
46 Blood was drawn from the antecubital vein for determinations of high-density
47
48 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
49
50 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
51
52 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
53
54 (enzymatic assay method) were measured at a commercially available laboratory (The
55
56
57
58
59
60

Endocrinology Laboratory, China Medical University, Shenyang, China).

Definition of MS, retinopathy, smoking, drinking and Diabetes

The International Diabetes Federation 2005 (IDF) standards describe a waist circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid abnormality; 2) HDL cholesterol < 1.29 mmol/L or specific treatment for this lipid abnormality; 3) raised blood pressure: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension; and 4) fasting plasma glucose ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic color fundus photographs were graded using the modified Airlie House classification and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}

The retinopathy was concerning about diabetic retinopathy except other microvascular changes namely vascular dilatation, focal narrowing and other changes. For each eye, the maximum grade in any of the seven standard photographic fields was determined for each of the lesions and used in defining the retinopathy levels. Drinking was defined as alcohol intake more than once per month during the past 12 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and currently smoking cigarettes

Statistical analyses

Mean \pm SD was used for measurement data. In univariate analysis, a *t*-test was applied for continuous variables and chi-square test (X^2) for nominal-scale data. Independent

1
2
3
4 risk factors for retinopathy were analyzed using multiple logistic regressions with
5
6 step-wise approach. Data management and statistical analyses were performed using
7
8 SPSS statistical software (Version 16.0, SPSS Inc., Chicago, IL). $P < 0.05$ was
9
10 considered statistically significant.
11
12

13 RESULTS

14
15 We recruited 1163 subjects mean age 67.09 ± 5.18 (40-82 years) in this study, which
16
17 contained 508 (43.68%) males. There were 498 subjects with MS. The overall
18
19 prevalence of MS was 42.82%. Table 1 showed that demographic data, selected
20
21 clinical and laboratory findings in patients with and without MS.
22
23
24
25

26
27 The prevalence for retinopathy was 9.64% ($n=48$) in patients with MS and 3.91%
28
29 ($n=26$) in patients without MS, respectively. Prevalence of retinopathy was
30
31 significantly higher in patients with MS ($p < 0.05$). Table 2 showed that the prevalence
32
33 of proliferative diabetic retinopathy (PDR) was significantly higher in patients with
34
35 MS ($p < 0.05$). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known
36
37 diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had
38
39 retinopathy (Fig. 1).
40
41
42
43
44

45
46 Demographic data, selected clinical and laboratory findings in patients with NPDR
47
48 and PDR were shown in Table 3. Patients with NPDR were significantly higher
49
50 prevalence with newly detected diabetes mellitus (DM).
51
52

53
54 In multiple logistic regression, independent risk factors for any retinopathy in patients
55
56 with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence
57
58
59
60

1
2
3
4 interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16;
5
6 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24;
7
8 95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95%
9
10 CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17;
11
12 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23;
13
14 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP,
15
16 were found for any retinopathy in patients without MS (Table 4).
17
18
19

20 21 **DISCUSSION**

22
23 The data reported population-based information regarding the prevalence of MS and
24
25 its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF
26
27 criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that
28
29 the prevalence of the MS was 13.7% in Chinese adult populations. However, the
30
31 prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that
32
33 the prevalence of MS was high and might be due to the number of Chinese elder
34
35 increasing and would be representing a problem of public health in social.
36
37
38
39

40
41 Previous population-based studies in nondiabetic persons have suggested a prevalence
42
43 of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%).
44
45 However, another study in China had reported that the prevalence of retinopathy
46
47 among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban,
48
49 which may explain partially the lower prevalence found in our study. The overall
50
51 prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the
52
53 results of previous meta-analysis in China.²⁶ Study by Keenan *et al.* showed that the
54
55
56
57
58
59
60

1
2
3
4 prevalence of retinopathy was 8.6% in patients with MS, and it was little lower than
5
6 our results. Similarly, the prevalence of retinopathy (3.6%) in patients without MS
7
8 was a slightly lower than that of this study.²⁴
9

10
11 To the best of our knowledge, it was the first population-based study provided
12
13 evidence that the relationship between MS and retinopathy in North Chinese
14
15 population, and MS is an independent risk factor of retinopathy after adjusting age,
16
17 gender and other factors. Previously, a community-based study in South China
18
19 (Shanghai) reported that retinopathy were highly associated with accumulated
20
21 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
22
23 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
24
25 have reported the association between the retinopathy and MS in subjects without
26
27 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
28
29 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
30
31 another study in Japan, a similar association was found.²⁹ Although the researchers in
32
33 these studies did not reveal the relationship between MS and retinopathy in the
34
35 non-diabetic population, it might be due to this cross-sectional study could not
36
37 prevent itself from being with methodological problems. The study design is
38
39 incapable of estimating causal relation directly. In addition, the results of our study
40
41 proved higher prevalence of retinopathy including PDR in patients with MS.
42
43
44 Therefore, we could hypotheses that MS as a risk factor for retinopathy in the subjects,
45
46
47 and more prospective studies are warranted to determine the significance of the MS
48
49 for predicting risk of retinopathy.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In this study, we found associations of some individual components of MS with a
5
6 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
7
8 variables, we also found that no matter the presence of MS or not, as defined by the
9
10 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
11
12 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
13
14 independent risk factors for retinopathy. Higher diastolic blood pressure was the
15
16 independent risk factor for retinopathy in patients with MS. HDL levels was not
17
18 associated with the presence of retinopathy lesions, and some early studies also have
19
20 revealed this conclusion.²⁴ According to our results, we also had not found significant
21
22 association between smoking and drinking in patients with or without MS.
23
24
25
26
27

28
29 The short coming for this study included it was a population based study in
30
31 community, so there were no fundus fluorescein angiography (FFA), and optical
32
33 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
34
35 in four communities of Shenyang, so there is a selection bias. In addition, we did not
36
37 investigate the type of diabetes for all subjects.
38
39
40

41
42 In summary, our data demonstrate the presence of MS and its components are
43
44 significantly associated with the prevalence of retinopathy. Rather, in order to prevent
45
46 retinopathy development, risk factors should be controlled in patients with or without
47
48 MS. More comprehensive studies are needed to clarify the roles of MS and also its
49
50 relationship with retinal vascular disorders.
51
52
53

54 **Acknowledgement**

55
56
57 Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Editing International, for help in the language editing of this manuscript.

Authors have no relevant conflict of interest to disclose.

Funding

This study was supported by National Natural Science Foundation of China (81300783); Liaoning Science and Technology Project (2009225005); Liaoning Department of Health Medical Peak of Construction Project (2010016); Important Platform of Science and Technology for the University in Liaoning Province (16010).

Contributors

L. L. and J.G. and Z.Y. and J.Y.W and J.L. and W.P.T. researched data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and D.D.H. wrote the manuscript.

REFERENCES

1. Lakka HM, Laaksonen DE, Lakka TA, *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;**288**:2709-16.
2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. *J Cardiometab Syndr* 2007;**2**:276-82.
3. Feng Y, Hong X, Li Z, *et al.* Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. *Obesity* 2006;**14**:2089-98.
4. Fang JN, Huang MA, Cui L, *et al.* Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;**34**:759-61.

- 1
2
3
4 5. Golden SH, Folsom AR, Coresh J, *et al.* Risk factor groupings related to insulin
5
6 resistance and their synergistic effects on subclinical atherosclerosis: the
7
8 atherosclerosis risk in communities study. *Diabetes* 2002;**51**:3069-76.
- 9
10
11 6. Wong TY, Duncan BB, Golden SH, *et al.* Associations between the metabolic
12
13 syndrome and retinal microvascular signs: the Atherosclerosis Risk In
14
15 Communities study. *Invest Ophthalmol Vis Sci* 2004;**45**:2949-54.
- 16
17
18 7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance
19
20 among adult women with metabolic syndrome. *Acta Med Indones* 2010;**42**:187-91.
- 21
22
23 8. Tung TH, Shih HC, Tsai ST, *et al.* A community-based study of the relationship
24
25 between insulin resistance/beta-cell dysfunction and diabetic retinopathy among
26
27 type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;**14**:148-54.
- 28
29
30 9. Anan F, Takayuki M, Takahashi N, *et al.* Diabetic retinopathy is associated with
31
32 insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic
33
34 patients. *Hypertens Res* 2009;**32**:299-305.
- 35
36
37
38 10. Zimmet P, Magliano D, Matsuzawa Y, *et al.* The metabolic syndrome: a global
39
40 public health problem and a new definition. *J Atheroscler Thromb*
41
42 2005;**12**:295-300.
- 43
44
45
46 11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for
47
48 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
49
50 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
51
52 1998 WHO consultation criteria, and 1985 WHO criteria. World Health
53
54 Organization. *Diabetes Res Clin Pract* 1999;**44**:21-6.
- 55
56
57
58
59
60

- 1
2
3
4 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
5
6 retinopathy from stereoscopic color fundus photographs--an extension of the
7
8 modified Airlie House classification. ETDRS report number 10. *Ophthalmology*
9
10 1991;**98**:786-806.
- 11
12
13 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
14
15 photographic risk factors for progression of diabetic retinopathy. ETDRS report
16
17 number 12. *Ophthalmology* 1991;**98**:823-33.
- 18
19
20 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
21
22 in a large professional population in Beijing. *Atherosclerosis* 2006;**184**:188-92.
- 23
24
25 15. Gu D, Reynolds K, Wu X, *et al*. Prevalence of the metabolic syndrome and
26
27 overweight among adults in China. *Lancet* 2005;**365**:1398-405.
- 28
29
30 16. He Y, Jiang B, Wang J, *et al*. Prevalence of the metabolic syndrome and its
31
32 relation to cardiovascular disease in an elderly Chinese population. *J Am Coll*
33
34 *Cardiol* 2006;**47**:1588-94.
- 35
36
37 17. Klein R, Klein BE, Moss SE, *et al*. Hypertension and retinopathy, arteriolar
38
39 narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol*
40
41 1994;**112**:92-8.
- 42
43
44 18. Yu T, Mitchell P, Berry G, *et al*. Retinopathy in older persons without diabetes
45
46 and its relationship to hypertension. *Arch Ophthalmol* 1998;**116**:83-9.
- 47
48
49 19. Hubbard LD, Brothers RJ, King WN, *et al*. Methods for evaluation of retinal
50
51 microvascular abnormalities associated with hypertension/sclerosis in the
52
53 Atherosclerosis Risk in Communities Study. *Ophthalmology* 1999;**106**:2269-80.
54
55
56
57
58
59
60

- 1
2
3
4 20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated
5
6 with retinopathy: the Hoorn Study. *Diabetes Care* 2002;**25**:1320-5.
7
8
9 21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal
10
11 microvascular abnormalities in older persons: the Cardiovascular Health Study.
12
13 *Ophthalmology* 2003;**110**:658-66.
14
15
16 22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated
17
18 with diabetic retinopathy in the Australian population. *Diabetes Care*
19
20 2003;**26**:1731-7.
21
22
23 23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal
24
25 microvascular signs in an adult Japanese population: the Funagata Study.
26
27 *Ophthalmology* 2006;**113**:1378-84.
28
29
30 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
31
32 metabolic syndrome: findings from the Third National Health and Nutrition
33
34 Examination Survey. *Am J Ophthalmol.* 2009;**147**:934-44, 944.e1-2.
35
36
37 25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes:
38
39 the Handan Eye Study. *Ophthalmology* 2010;**117**:531-7, 537.e1-2.
40
41
42 26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China:
43
44 a meta-analysis. *PLoS One* 2012;**7**:e45264.
45
46
47 27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular
48
49 diseases in Chinese community-based subjects with various metabolic
50
51 abnormalities. *PLoS One* 2014;**9**:e97928.
52
53
54 28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic
55
56
57
58
59
60

1
2
3
4 syndrome and diabetic microangiopathy. *Exp Ther Med* 2014;**8**:1867-73.

- 5
6 29. Kawasaki R, Tielsch JM, Wang JJ, *et al*. The metabolic syndrome and retinal
7
8 microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol*
9
10 2008;**92**:161-6.
11
12

13
14 **Figure legend:**

15
16 Fig. 1: Prevalence of retinopathy in different groups of this study. MS: metabolic
17
18 syndrome.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS(<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001
Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001
DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001
Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (<i>n</i> =48)	Without MS (<i>n</i> =26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

For peer review only

Table 3. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	p-value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001
Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001
DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001
Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.


Table 4. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR* (95% CI)	p-value	OR# (95% CI)	p-value	OR* (95% CI)	p-value	OR# (95% CI)	p-value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60
Diabetes duration (per 10-year)	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55
SBP (per 10-mmHg)	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
DBP (per 10-mmHg)	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
Triglycerides (per 10-mg/dL)	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39
HDL cholesterol (per 10-mg/dL)	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
FPG (per 10-mg/dL)	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
2hPPG (per 10-mg/dL)	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
HbA _{1c} (per % (mmol/mol))	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected DM	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



149x130mm (300 x 300 DPI)

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855.R1
Article Type:	Research
Date Submitted by the Author:	04-Aug-2015
Complete List of Authors:	Liu, Lei; The First Affiliated Hospital of China Medical University., ophthalmology Wu, Jingyang; The First Affiliated Hospital of China Medical University., ophthalmology; The First Affiliated Hospital of China Medical University., ophthalmology Yue, Song; The First Affiliated Hospital of China Medical University., ophthalmology Zhang, Jiahua; The First Affiliated Hospital of China Medical University., ophthalmology Lian, Jie; ophthalmology Teng, Weiping; The First Affiliated Hospital of China Medical University., Key Laboratory of Endocrine Diseases in Liaoning Province Huang, Desheng; School of Public Health, China Medical University., Epidemiology Chen, Lei; The First Affiliated Hospital of China Medical University., ophthalmology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Jingyang Wu^{#1}, Song Yue¹, Jiahua Zhang¹, Jie Lian², Weiping Teng³, Desheng Huang^{4*}, Lei Chen^{1,3*}.

Authors' illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3 Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,
4
5

6 P.R. China 110001
7

8
9 Tel: +86-13889378662 Fax:+86-24-83283590
10

11 E-mail: huangdsll@163.com
12
13

14 **Prof. Lei Chen**
15

16
17 Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,
18

19 P.R. China 110122
20

21
22 Tel: +86-13889378662 Fax:+86-24-83282630
23

24 E-mail: carol1422@163.com
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

Design: A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District.

Primary and secondary outcome measures: A total of 1163 eligible participants attended this research. All the participants were took the stereo fundus photography to detect retinopathy. The discrepancy of prevalence for retinopathy in different participants was described.

Results: The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI,1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase).

Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

Strengths and limitations of this study

- It was the first population-based study provided evidence that the relationship between MS and retinopathy in North Chinese population.
- We found that the presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.
- We did not investigate the type of diabetes for all subjects. So the prevalence of retinopathy in diabetes was lower representative.

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with

1
2
3
4 insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It
5
6 is unclear whether the MS is associated with retinopathy in North Chinese population.
7
8
9 The retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were
10
11 differentiated in this study. We examined the cross-sectional association of the MS
12
13 and retinopathy in this population-based study.
14

15 16 **METHODS**

17 18 Study population

19
20
21 There were more than 80,000 residents and five communities (including Yutan,
22
23 Yonghuan, Taoyuan, Qingnian and Zhongxin community) in Fengyutan Sub-District,
24
25 Shenyang, and North China. Firstly, four communities were randomly selected from
26
27 five communities in Fengyutan Sub-District. Secondly, 400 households in each of
28
29 four selected communities were randomly chosen. The participants had lived in
30
31 Fengyutan for at least two years at the time the research was conducted. Then the
32
33 selected households were informed by community officers using message or
34
35 telephone call. Finally, a total of 1400 subjects, aged over 40 years were randomly
36
37 recruited from August 2013 to September 2014. After excluding the patients with
38
39 cancer, hepatic failure, renal failure, severe psychiatric disturbance, any other
40
41 systemic medical condition e.g. severe cardiac impairment or severe respiratory
42
43 impairment, and subjects who did not want to attend this study voluntarily, a total of
44
45 1163 (response rate 83.07%) eligible participants attended this research. Subjects
46
47 were not attended this study voluntarily or with serious illness such as cancer, liver
48
49 and kidney function failure were excluded.
50
51
52
53
54
55
56
57
58
59
60

Data collection

Information on name, gender, age, smoking, drinking, and health status such as duration of diabetes, hypertension duration, past medical history and treatment methods were obtained using a standardized questionnaire. In addition, participants were asked whether they suffer from DM and if the diagnosis was made by a physician. All subjects were also asked to provide information on their current medication. Thus, known diabetes was defined according to self-reported physician diagnosis or the use of anti-diabetic agents. Following a community office worker interview, all participants were asked to fast overnight (>8 hours) before a physical examination. Waist circumference was measured at the level of the umbilicus in the standing position. Height and weight were measured without wearing hats or heavy coats. Blood pressure (BP) was measured in the sitting position (first) and supine position (second) at a 5-min interval using an upright standard sphygmomanometer. Vigorous physical activity and smoking were avoided for at least 30 min before BP measurement. The second BP measurement with the fifth phase diastolic pressure was used for analysis. All the participants were took the stereo fundus photography to detect retinopathy by 45° Non-Mydriatic Fundus Camera (CR6-45NM, Canon, Tokyo, Japan) through undilated pupils. For each subject, two images for each eye centered on the fovea and optic disk were taken in the physiologically within a darkened room. Each image was graded in a masked manner by two well-trained ophthalmologists separately for the presence of retinopathy lesions. If the grades were inconsistent, the other ophthalmologist would give the final diagnosis. The grade of

1
2
3
4 retinopathy for each eye was determined and the individual classification was based
5
6 upon the worse eye. There were 41 subjects that could not get a clear retinal image
7
8 because anterior segment opacity. They accepted mydriasis with tropicamide 1%
9
10 (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before 20 minutes of dark adaptation
11
12 and binocular indirect ophthalmoscope by two ophthalmologists who reviewed retinal
13
14 images.
15
16

17
18
19 The mayor and the welfare section of Fengyutan Sub-District approved this study. The
20
21 research followed the tenets of the Declaration of Helsinki and informed consent was
22
23 obtained from the subjects after explanation of the nature and possible consequences
24
25 of the study and the research was approved by Institutional Ethics Committee of The
26
27 First Affiliated Hospital of China Medical University.
28
29

30 31 32 Laboratory methods

33
34 Blood was drawn from the antecubital vein for determinations of high-density
35
36 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
37
38 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
39
40 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
41
42 (enzymatic assay method) were measured at a commercially available laboratory (The
43
44 Endocrinology Laboratory, China Medical University, and Shenyang, China).
45
46
47

48 49 50 Definition of MS, retinopathy, smoking, drinking and Diabetes

51
52 The International Diabetes Federation 2005 (IDF) standards describe a waist
53
54 circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the
55
56 following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid
57
58
59
60

1
2
3
4 abnormality; 2) HDL cholesterol <1.29 mmol/L or specific treatment for this lipid
5
6 abnormality; 3) raised blood pressure: systolic blood pressure \geq 130 mmHg or
7
8 diastolic blood pressure \geq 85 mmHg, or treatment of previously diagnosed
9
10 hypertension; and 4) fasting plasma glucose \geq 5.6 mmol/L or previously diagnosed
11
12 type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic
13
14 color fundus photographs were graded using the modified Airlie House classification
15
16 and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}
17
18 The retinopathy was concerning about diabetic retinopathy except other
19
20 microvascular changes namely vascular dilatation, focal narrowing and other changes.
21
22

23
24 For each eye, the maximum grade in any of the seven standard photographic fields
25
26 was determined for each of the lesions and used in defining the retinopathy levels.
27
28

29
30 Drinking was defined as alcohol intake more than once per month during the past 12
31
32 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and
33
34 currently smoking cigarettes.
35
36

37 38 39 Statistical analyses

40
41 Mean \pm SD was used for measurement data. In univariate analysis, a *t*-test was applied
42
43 for continuous variables and chi-square test (X^2) for nominal-scale data. Independent
44
45 risk factors for retinopathy were analyzed using multiple logistic regressions with
46
47 step-wise approach. Data management and statistical analyses were performed using
48
49 SPSS statistical software (Version 16.0, SPSS Inc., and Chicago, IL). $P < 0.05$ was
50
51 considered statistically significant.
52
53
54
55

56 57 58 59 60 **RESULTS**

~~We recruited 1163 subjects mean age 67.09 ± 5.18 (40-82 years) in this study, which contained 508 (43.68%) males.~~ There were 498 subjects with MS. The overall prevalence of MS was 42.82%. Table 1 showed that demographic data, selected clinical and laboratory findings in patients with and without MS.

The prevalence for retinopathy was 9.64% (n=48) in patients with MS and 3.91% (n=26) in patients without MS, respectively. Prevalence of retinopathy was significantly higher in patients with MS (p<0.05). Table 2 showed that the prevalence of proliferative diabetic retinopathy (PDR) was significantly higher in patients with MS (p<0.05). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had retinopathy in Table 3. The characteristics of patients with retinopathy in nondiabetic persons were shown in Table 4.

Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR were shown in Table 5. Patients with NPDR were significantly higher prevalence with newly detected diabetes mellitus (DM).

In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24; 95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17;

95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23; 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS (Table 6).

DISCUSSION

The data reported population-based information regarding the prevalence of MS and its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that the prevalence of the MS was 13.7% in Chinese adult populations. However, the prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that the prevalence of MS was high and might be due to the number of Chinese elder increasing and would be representing a problem of public health in social.

Previous population-based studies in nondiabetic persons have suggested a prevalence of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%). However, another study in China had reported that the prevalence of retinopathy among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban, which may explain partially the lower prevalence found in our study. The overall prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the results of previous meta-analysis in China.²⁶ In our study, the retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were differentiated. Study by Keenan *et al.* showed that the prevalence of retinopathy was 8.6% in patients with MS, and it was little lower than our results. Similarly, the prevalence of retinopathy (3.6%) in patients without MS was a slightly lower than that of this study.²⁴

1
2
3
4 To the best of our knowledge, it was the first population-based study provided
5
6 evidence that the relationship between MS and retinopathy in North Chinese
7
8 population, and MS is an independent risk factor of retinopathy after adjusting age,
9
10 gender and other factors. Previously, a community-based study in South China
11
12 (Shanghai) reported that retinopathy were highly associated with accumulated
13
14 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
15
16 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
17
18 have reported the association between the retinopathy and MS in subjects without
19
20 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
21
22 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
23
24 another study in Japan, a similar association was found.²⁹ Although the researchers in
25
26 these studies did not reveal the relationship between MS and retinopathy in the
27
28 non-diabetic population, it might be due to this cross-sectional study could not
29
30 prevent itself from being with methodological problems. The study design is
31
32 incapable of estimating causal relation directly. In addition, the results of our study
33
34 proved higher prevalence of retinopathy including PDR in patients with MS.
35
36 Therefore, we could hypotheses that MS as a risk factor for retinopathy in the subjects,
37
38 and more prospective studies are warranted to determine the significance of the MS
39
40 for predicting risk of retinopathy.
41
42

43
44 In this study, we found associations of some individual components of MS with a
45
46 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
47
48 variables, we also found that no matter the presence of MS or not, as defined by the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
5
6 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
7
8 independent risk factors for retinopathy. Higher diastolic blood pressure was the
9
10 independent risk factor for retinopathy in patients with MS. HDL levels was not
11
12 associated with the presence of retinopathy lesions, and some early studies also have
13
14 revealed this conclusion.²⁴ According to our results, we also had not found significant
15
16 association between smoking and drinking in patients with or without MS.
17
18

19
20 The short coming for this study included it was a population based study in
21
22 community, so there were no fundus fluorescein angiography (FFA), and optical
23
24 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
25
26 in four communities of Shenyang, so there is a selection bias. In addition, we did not
27
28 investigate the type of diabetes for all subjects. So the prevalence of retinopathy in
29
30 diabetes was lower representative.
31
32
33
34

35 36 CONCLUSION

37
38 In summary, our data demonstrate the presence of MS components is significantly
39
40 associated with the prevalence of retinopathy. Rather, in order to prevent retinopathy
41
42 development, risk factors should be controlled in patients with or without MS. More
43
44 comprehensive studies are needed to clarify the roles of MS and also its relationship
45
46 with retinal vascular disorders.
47
48
49
50

51 52 Acknowledgement

53
54 Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical
55
56 Editing International, for help in the language editing of this manuscript.
57
58
59
60

Contributors: L. L. and S.Y. and J.H.Z. and J.Y.W and J.L. and W.P.T. researched data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and D.D.H. wrote the manuscript. All authors have given their final approval of this manuscript.

Funding

This study was funded by National Natural Science Foundation of China (81300783); Liaoning Science and Technology Project (2009225005); Liaoning Department of Health Medical Peak of Construction Project (2010016); Important Platform of Science and Technology for the University in Liaoning Province (16010).

Competing interests: None declared.

Ethics approval: The study was approved by the Ethics Committee of The First Affiliated Hospital Of China Medical University.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

REFERENCES

1. Lakka HM, Laaksonen DE, Lakka TA, *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-16.
2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. *J Cardiometab Syndr* 2007;2:276-82.
3. Feng Y, Hong X, Li Z, *et al.* Prevalence of metabolic syndrome and its relation to

- body composition in a Chinese rural population. *Obesity* 2006;14:2089-98.
4. Fang JN, Huang MA, Cui L, *et al.* Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;34:759-61.
5. Golden SH, Folsom AR, Coresh J, *et al.* Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002;51:3069-76.
6. Wong TY, Duncan BB, Golden SH, *et al.* Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004;45:2949-54.
7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. *Acta Med Indones* 2010;42:187-91.
8. Tung TH, Shih HC, Tsai ST, *et al.* A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;14:148-54.
9. Anan F, Takayuki M, Takahashi N, *et al.* Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. *Hypertens Res* 2009;32:299-305.
10. Zimmet P, Magliano D, Matsuzawa Y, *et al.* The metabolic syndrome: a global public health problem and a new definition. *J Atheroscler Thromb* 2005;12:295-300.
11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for

1
2
3
4 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
5
6 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
7
8 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.
9
10
11 Diabetes Res Clin Pract 1999;44:21-6.

12
13
14 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
15
16 retinopathy from stereoscopic color fundus photographs--an extension of the modified
17
18 Airlie House classification. ETDRS report number 10. Ophthalmology
19
20
21 1991;98:786-806.

22
23
24 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
25
26 photographic risk factors for progression of diabetic retinopathy. ETDRS report
27
28 number 12. Ophthalmology 1991;98:823-33.

29
30
31
32 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
33
34 in a large professional population in Beijing. Atherosclerosis 2006;184:188-92.

35
36
37 15. Gu D, Reynolds K, Wu X, *et al*. Prevalence of the metabolic syndrome and
38
39 overweight among adults in China. Lancet 2005;365:1398-405.

40
41
42 16. He Y, Jiang B, Wang J, *et al*. Prevalence of the metabolic syndrome and its
43
44 relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol
45
46 2006;47:1588-94.

47
48
49 17. Klein R, Klein BE, Moss SE, *et al*. Hypertension and retinopathy, arteriolar
50
51 narrowing, and arteriovenous nicking in a population. Arch Ophthalmol
52
53 1994;112:92-8.

- 1
2
3
4 18. Yu T, Mitchell P, Berry G, *et al.* Retinopathy in older persons without diabetes and
5
6 its relationship to hypertension. *Arch Ophthalmol* 1998;116:83-9.
7
8
9 19. Hubbard LD, Brothers RJ, King WN, *et al.* Methods for evaluation of retinal
10
11 microvascular abnormalities associated with hypertension/sclerosis in the
12
13 Atherosclerosis Risk in Communities Study. *Ophthalmology* 1999;106:2269-80.
14
15
16 20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated
17
18 with retinopathy: the Hoorn Study. *Diabetes Care* 2002;25:1320-5.
19
20
21 21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal
22
23 microvascular abnormalities in older persons: the Cardiovascular Health Study.
24
25
26
27
28
29
30 22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated
31
32 with diabetic retinopathy in the Australian population. *Diabetes Care* 2003;26:1731-7.
33
34
35 23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal
36
37 microvascular signs in an adult Japanese population: the Funagata Study.
38
39
40
41
42
43
44 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
45
46 metabolic syndrome: findings from the Third National Health and Nutrition
47
48 Examination Survey. *Am J Ophthalmol.* 2009;147:934-44, 944.e1-2.
49
50
51 25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes: the
52
53 Handan Eye Study. *Ophthalmology* 2010;117:531-7, 537.e1-2.
54
55
56 26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China: a
57
58
59
60

meta-analysis. PLoS One 2012;7:e45264.

27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular diseases in Chinese community-based subjects with various metabolic abnormalities. PLoS One 2014;9:e97928.

28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy. Exp Ther Med 2014;8:1867-73.

29. Kawasaki R, Tielsch JM, Wang JJ, *et al.* The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. Br J Ophthalmol 2008;92:161-6.

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS (<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001
Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001
DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001
Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR:

odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (<i>n</i> =48)	Without MS (<i>n</i> =26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

Table 3. Prevalence of retinopathy in different groups of this study.

Item	Retinopathy (n)	Prevalence (%)
Total diabetes	55	11.79
Known diabetes	34	18.18

Newly detected diabetes	21	7.72
Non-diabetes	19	3.25
With MS	48	9.64
Without MS	26	3.91
Total subjects	74	6.36

MS: metabolic syndrome.

Table 4. Demographic data, selected clinical and laboratory findings in retinopathy patients with nondiabetes.

Parameter	Retinopathy patients with nondiabetes
Age (years)	59.1 ±3.2
Male (%)	44.3
Weight (kg)	75.3 ±11.6
Height (cm)	169.8 ±11.1
BMI (kg/m ²)	28.9 ±5.1
Waist (cm)	95.5 ±8.9
SBP (mmHg)	126.3 ±11.6
DBP (mmHg)	79.5 ±9.1
Triglyceride (mg/dL)	148.5±10.6
HDL (mg/dL)	66.3 ±18.1
FPG (mg/dL)	98.7 ±10.5
2hPPG (mg/dL)	189.8±10.5
HbA _{1c} (% (mmol/mol))	5.2±0.6
Smoking (%)	32.1
Drinking (%)	41.8

BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; SBP: systolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 5. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	<i>p</i> -value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001
Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001
DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001
Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index;

DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP:

systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 6. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60
Diabetes duration (per 10-year)	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55
SBP (per 10-mmHg)	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
DBP (per 10-mmHg)	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
Triglycerides (per 10-mmHg)	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39

10-mg/dL)								
HDL cholesterol	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
(per 10-mg/dL)								
FPG (per	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
10-mg/dL)								
2hPPG (per	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
10-mg/dL)								
HbA _{1c} (per %	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
(mmol/mol))								
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35
DM								

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-8
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855.R2
Article Type:	Research
Date Submitted by the Author:	19-Aug-2015
Complete List of Authors:	Liu, Lei; The First Affiliated Hospital of China Medical University., ophthalmology Wu, Jingyang; The First Affiliated Hospital of China Medical University., ophthalmology; The First Affiliated Hospital of China Medical University., ophthalmology Yue, Song; The First Affiliated Hospital of China Medical University., ophthalmology Zhang, Jiahua; The First Affiliated Hospital of China Medical University., ophthalmology Lian, Jie; ophthalmology Teng, Weiping; The First Affiliated Hospital of China Medical University., Key Laboratory of Endocrine Diseases in Liaoning Province Huang, Desheng; School of Public Health, China Medical University., Epidemiology Chen, Lei; The First Affiliated Hospital of China Medical University., ophthalmology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Jingyang Wu^{#1}, Song Yue¹, Jiahua Zhang¹, Jie Lian², Weiping Teng³, Desheng Huang^{4*}, Lei Chen^{1,3*}.

Authors' illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3
4 Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,
5
6
7

8
9
10
11 P.R. China 110001
12

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tel: +86-13889378662 Fax:+86-24-83283590

E-mail: huangdsll@163.com

Prof. Lei Chen

Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,

P.R. China 110122

Tel: +86-13889378662 Fax:+86-24-83282630

E-mail: carol1422@163.com

ABSTRACT

Objectives: To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

Design: A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District.

Primary and secondary outcome measures: A total of 1163 eligible participants attended this research. All the participants were took the stereo fundus photography to detect retinopathy. The discrepancy of prevalence for retinopathy in different participants was described.

Results: The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI,1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase).

Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

Strengths and limitations of this study

- It was the first population-based study provided evidence that the relationship between MS and retinopathy in North Chinese population.
- We found that the presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.
- We did not investigate the type of diabetes for all subjects. So the prevalence of retinopathy in diabetes was lower representative.

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with

1
2
3 insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It
4
5
6 is unclear whether the MS is associated with retinopathy in North Chinese population.
7
8
9 The retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were
10
11 differentiated in this study. We examined the cross-sectional association of the MS
12
13 and retinopathy in this population-based study.
14

15 16 **METHODS**

17 18 Study population

19
20
21 There were more than 80,000 residents and five communities (including Yutan,
22
23 Yonghuan, Taoyuan, Qingnian and Zhongxin community) in Fengyutan Sub-District,
24
25 Shenyang, and North China. Firstly, four communities were randomly selected from
26
27 five communities in Fengyutan Sub-District. Secondly, 400 households in each of
28
29 four selected communities were randomly chosen. The participants had lived in
30
31 Fengyutan for at least two years at the time the research was conducted. Then the
32
33 selected households were informed by community officers using message or
34
35 telephone call. Finally, a total of 1400 subjects, aged over 40 years were randomly
36
37 recruited from August 2013 to September 2014. After excluding the patients with
38
39 cancer, hepatic failure, renal failure, severe psychiatric disturbance, any other
40
41 systemic medical condition e.g. severe cardiac impairment or severe respiratory
42
43 impairment, and subjects who did not want to attend this study voluntarily, a total of
44
45 1163 (response rate 83.07%) eligible participants attended this research. Subjects
46
47 were not attended this study voluntarily or with serious illness such as cancer, liver
48
49 and kidney function failure were excluded.
50
51
52
53
54
55
56
57
58
59
60

Data collection

Information on name, gender, age, smoking, drinking, and health status such as duration of diabetes, hypertension duration, past medical history and treatment methods were obtained using a standardized questionnaire. In addition, participants were asked whether they suffer from DM and if the diagnosis was made by a physician. All subjects were also asked to provide information on their current medication. Thus, known diabetes was defined according to self-reported physician diagnosis or the use of anti-diabetic agents. Following a community office worker interview, all participants were asked to fast overnight (>8 hours) before a physical examination. Waist circumference was measured at the level of the umbilicus in the standing position. Height and weight were measured without wearing hats or heavy coats. Blood pressure (BP) was measured in the sitting position (first) and supine position (second) at a 5-min interval using an upright standard sphygmomanometer. Vigorous physical activity and smoking were avoided for at least 30 min before BP measurement. The second BP measurement with the fifth phase diastolic pressure was used for analysis. All the participants were took the stereo fundus photography to detect retinopathy by 45° Non-Mydriatic Fundus Camera (CR6-45NM, Canon, Tokyo, Japan) through undilated pupils. For each subject, two images for each eye centered on the fovea and optic disk were taken in the physiologically within a darkened room. Each image was graded in a masked manner by two well-trained ophthalmologists separately for the presence of retinopathy lesions. If the grades were inconsistent, the other ophthalmologist would give the final diagnosis. The grade of

1
2
3
4 retinopathy for each eye was determined and the individual classification was based
5
6 upon the worse eye. There were 41 subjects that could not get a clear retinal image
7
8 because anterior segment opacity. They accepted mydriasis with tropicamide 1%
9
10 (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before 20 minutes of dark adaptation
11
12 and binocular indirect ophthalmoscope by two ophthalmologists who reviewed retinal
13
14 images.
15
16

17
18
19 The mayor and the welfare section of Fengyutan Sub-District approved this study. The
20
21 research followed the tenets of the Declaration of Helsinki and informed consent was
22
23 obtained from the subjects after explanation of the nature and possible consequences
24
25 of the study and the research was approved by Institutional Ethics Committee of The
26
27 First Affiliated Hospital of China Medical University.
28
29

30 31 32 Laboratory methods

33
34 Blood was drawn from the antecubital vein for determinations of high-density
35
36 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
37
38 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
39
40 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
41
42 (enzymatic assay method) were measured at a commercially available laboratory (The
43
44 Endocrinology Laboratory, China Medical University, and Shenyang, China).
45
46
47

48 49 50 Definition of MS, retinopathy, smoking, drinking and Diabetes

51
52 The International Diabetes Federation 2005 (IDF) standards describe a waist
53
54 circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the
55
56 following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid
57
58
59
60

1
2
3
4 abnormality; 2) HDL cholesterol <1.29 mmol/L or specific treatment for this lipid
5
6 abnormality; 3) raised blood pressure: systolic blood pressure \geq 130 mmHg or
7
8 diastolic blood pressure \geq 85 mmHg, or treatment of previously diagnosed
9
10 hypertension; and 4) fasting plasma glucose \geq 5.6 mmol/L or previously diagnosed
11
12 type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic
13
14 color fundus photographs were graded using the modified Airlie House classification
15
16 and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}
17
18 The retinopathy was concerning about diabetic retinopathy except other
19
20 microvascular changes namely vascular dilatation, focal narrowing and other changes.
21
22 For each eye, the maximum grade in any of the seven standard photographic fields
23
24 was determined for each of the lesions and used in defining the retinopathy levels.
25
26 Drinking was defined as alcohol intake more than once per month during the past 12
27
28 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and
29
30 currently smoking cigarettes.

31 32 33 34 35 36 37 38 39 Statistical analyses

40
41 Mean \pm SD was used for measurement data. In univariate analysis, a *t*-test was applied
42
43 for continuous variables and chi-square test (X^2) for nominal-scale data. Independent
44
45 risk factors for retinopathy were analyzed using multiple logistic regressions with
46
47 step-wise approach. Data management and statistical analyses were performed using
48
49 SPSS statistical software (Version 16.0, SPSS Inc., and Chicago, IL). *P*<0.05 was
50
51 considered statistically significant.
52
53
54
55

56 57 58 59 60 **RESULTS**

1
2
3
4 There were 498 subjects with MS. The overall prevalence of MS was 42.82%. Table 1
5
6 showed that demographic data, selected clinical and laboratory findings in patients
7
8 with and without MS.
9

10
11 The prevalence for retinopathy was 9.64% (n=48) in patients with MS and 3.91%
12
13 (n=26) in patients without MS, respectively. Prevalence of retinopathy was
14
15 significantly higher in patients with MS ($p<0.05$). Table 2 showed that the prevalence
16
17 of proliferative diabetic retinopathy (PDR) was significantly higher in patients with
18
19 MS ($p<0.05$). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known
20
21 diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had
22
23 retinopathy in Table 3. The characteristics of patients with retinopathy in nondiabetic
24
25 persons were shown in Table 4.
26
27
28
29
30
31

32
33 Demographic data, selected clinical and laboratory findings in patients with NPDR
34
35 and PDR were shown in Table 5. Patients with NPDR were significantly higher
36
37 prevalence with newly detected diabetes mellitus (DM).
38
39
40

41
42 In multiple logistic regression, independent risk factors for any retinopathy in patients
43
44 with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence
45
46 interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16;
47
48 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24;
49
50 95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95%
51
52 CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17;
53
54 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23;
55
56
57
58
59
60

95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS (Table 6).

DISCUSSION

The data reported population-based information regarding the prevalence of MS and its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that the prevalence of the MS was 13.7% in Chinese adult populations. However, the prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that the prevalence of MS was high and might be due to the number of Chinese elder increasing and would be representing a problem of public health in social.

Previous population-based studies in nondiabetic persons have suggested a prevalence of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%). However, another study in China had reported that the prevalence of retinopathy among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban, which may explain partially the lower prevalence found in our study. The overall prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the results of previous meta-analysis in China.²⁶ In our study, the retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were differentiated. Study by Keenan *et al.* showed that the prevalence of retinopathy was 8.6% in patients with MS, and it was little lower than our results. Similarly, the prevalence of retinopathy (3.6%) in patients without MS was a slightly lower than that of this study.²⁴

To the best of our knowledge, it was the first population-based study provided

1
2
3
4 evidence that the relationship between MS and retinopathy in North Chinese
5
6 population, and MS is an independent risk factor of retinopathy after adjusting age,
7
8 gender and other factors. Previously, a community-based study in South China
9
10 (Shanghai) reported that retinopathy were highly associated with accumulated
11
12 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
13
14 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
15
16 have reported the association between the retinopathy and MS in subjects without
17
18 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
19
20 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
21
22 another study in Japan, a similar association was found.²⁹ Although the researchers in
23
24 these studies did not reveal the relationship between MS and retinopathy in the
25
26 non-diabetic population, it might be due to this cross-sectional study could not
27
28 prevent itself from being with methodological problems. The study design is
29
30 incapable of estimating causal relation directly. In addition, the results of our study
31
32 proved higher prevalence of retinopathy including PDR in patients with MS.
33
34 Therefore, we could hypotheses that MS as a risk factor for retinopathy in the subjects,
35
36 and more prospective studies are warranted to determine the significance of the MS
37
38 for predicting risk of retinopathy.

39
40
41 In this study, we found associations of some individual components of MS with a
42
43 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
44
45 variables, we also found that no matter the presence of MS or not, as defined by the
46
47 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
5
6 independent risk factors for retinopathy. Higher diastolic blood pressure was the
7
8 independent risk factor for retinopathy in patients with MS. HDL levels was not
9
10 associated with the presence of retinopathy lesions, and some early studies also have
11
12 revealed this conclusion.²⁴ According to our results, we also had not found significant
13
14 association between smoking and drinking in patients with or without MS.
15
16

17
18 The short coming for this study included it was a population based study in
19
20 community, so there were no fundus fluorescein angiography (FFA), and optical
21
22 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
23
24 in four communities of Shenyang, so there is a selection bias. In addition, we did not
25
26 investigate the type of diabetes for all subjects. According to study design in
27
28 community, it was difficult to separate metabolic syndrome and diabetes, further
29
30 studies are needed to investigate the association between retinopathy and metabolic
31
32 syndrome patients without diabetes. So the prevalence of retinopathy in diabetes was
33
34 lower representative. In our study, we used indirect ophthalmoscopy to detect
35
36 retinopathy for the patients with difficulties in funds examination, this methods could
37
38 only detect cases with advanced retinopathy nor mild retinopathy cases. In future, we
39
40 will use non contact or contact lens under biomicroscopy to detect retinopathy.
41
42
43
44
45
46
47
48

49 CONCLUSION

50
51 In summary, our data demonstrate the presence of MS components is significantly
52
53 associated with the prevalence of retinopathy. Rather, in order to prevent retinopathy
54
55 development, risk factors should be controlled in patients with or without MS. More
56
57
58
59
60

comprehensive studies are needed to clarify the roles of MS and also its relationship with retinal vascular disorders.

Acknowledgement

Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical Editing International, for help in the language editing of this manuscript.

Contributors: L. L. and S.Y. and J.H.Z. and J.Y.W and J.L. and W.P.T. researched data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and D.D.H. wrote the manuscript. All authors have given their final approval of this manuscript.

Funding

This study was funded by National Natural Science Foundation of China (81300783); Liaoning Science and Technology Project (2009225005); Liaoning Department of Health Medical Peak of Construction Project (2010016); Important Platform of Science and Technology for the University in Liaoning Province (16010).

Competing interests: None declared.

Ethics approval: The study was approved by the Ethics Committee of The First Affiliated Hospital Of China Medical University.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

REFERENCES

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Lakka HM, Laaksonen DE, Lakka TA, *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-16.
2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. *J Cardiometab Syndr* 2007;2:276-82.
3. Feng Y, Hong X, Li Z, *et al.* Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. *Obesity* 2006;14:2089-98.
4. Fang JN, Huang MA, Cui L, *et al.* Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;34:759-61.
5. Golden SH, Folsom AR, Coresh J, *et al.* Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002;51:3069-76.
6. Wong TY, Duncan BB, Golden SH, *et al.* Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004;45:2949-54.
7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. *Acta Med Indones* 2010;42:187-91.
8. Tung TH, Shih HC, Tsai ST, *et al.* A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;14:148-54.
9. Anan F, Takayuki M, Takahashi N, *et al.* Diabetic retinopathy is associated with

- 1
2
3
4 insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic
5
6 patients. *Hypertens Res* 2009;32:299-305.
7
8
9 10. Zimmet P, Magliano D, Matsuzawa Y, *et al.* The metabolic syndrome: a global
10
11 public health problem and a new definition. *J Atheroscler Thromb* 2005;12:295-300.
12
13
14 11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for
15
16 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
17
18 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
19
20 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.
21
22 *Diabetes Res Clin Pract* 1999;44:21-6.
23
24
25 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
26
27 retinopathy from stereoscopic color fundus photographs--an extension of the modified
28
29 Airlie House classification. ETDRS report number 10. *Ophthalmology*
30
31 1991;98:786-806.
32
33
34 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
35
36 photographic risk factors for progression of diabetic retinopathy. ETDRS report
37
38 number 12. *Ophthalmology* 1991;98:823-33.
39
40
41
42 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
43
44 in a large professional population in Beijing. *Atherosclerosis* 2006;184:188-92.
45
46
47
48 15. Gu D, Reynolds K, Wu X, *et al.* Prevalence of the metabolic syndrome and
49
50 overweight among adults in China. *Lancet* 2005;365:1398-405.
51
52
53
54 16. He Y, Jiang B, Wang J, *et al.* Prevalence of the metabolic syndrome and its
55
56
57
58
59
60

1
2
3
4 relation to cardiovascular disease in an elderly Chinese population. *J Am Coll Cardiol*
5
6 2006;47:1588-94.
7

8
9 17. Klein R, Klein BE, Moss SE, *et al.* Hypertension and retinopathy, arteriolar
10
11 narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol*
12
13 1994;112:92-8.
14

15
16 18. Yu T, Mitchell P, Berry G, *et al.* Retinopathy in older persons without diabetes and
17
18 its relationship to hypertension. *Arch Ophthalmol* 1998;116:83-9.
19

20
21 19. Hubbard LD, Brothers RJ, King WN, *et al.* Methods for evaluation of retinal
22
23 microvascular abnormalities associated with hypertension/sclerosis in the
24
25 Atherosclerosis Risk in Communities Study. *Ophthalmology* 1999;106:2269-80.
26
27

28
29 20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated
30
31 with retinopathy: the Hoorn Study. *Diabetes Care* 2002;25:1320-5.
32
33

34
35 21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal
36
37 microvascular abnormalities in older persons: the Cardiovascular Health Study.
38
39 *Ophthalmology* 2003;110:658-66.
40

41
42 22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated
43
44 with diabetic retinopathy in the Australian population. *Diabetes Care* 2003;26:1731-7.
45
46

47
48 23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal
49
50 microvascular signs in an adult Japanese population: the Funagata Study.
51
52 *Ophthalmology* 2006;113:1378-84.
53
54

55
56 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
57
58
59
60

- metabolic syndrome: findings from the Third National Health and Nutrition Examination Survey. *Am J Ophthalmol.* 2009;147:934-44, 944.e1-2.
25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes: the Handan Eye Study. *Ophthalmology* 2010;117:531-7, 537.e1-2.
26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China: a meta-analysis. *PLoS One* 2012;7:e45264.
27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular diseases in Chinese community-based subjects with various metabolic abnormalities. *PLoS One* 2014;9:e97928.
28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy. *Exp Ther Med* 2014;8:1867-73.
29. Kawasaki R, Tielsch JM, Wang JJ, *et al.* The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol* 2008;92:161-6.

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS (<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001
Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001

DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001
Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (n=48)	Without MS (n=26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

Table 3. Prevalence of retinopathy in different groups of this study.

Item	Retinopathy (n)	Prevalence (%)
Total diabetes	55	11.79
Known diabetes	34	18.18
Newly detected diabetes	21	7.72
Non-diabetes	19	3.25
With MS	48	9.64
Without MS	26	3.91
Total subjects	74	6.36

MS: metabolic syndrome.

Table 4. Demographic data, selected clinical and laboratory findings in retinopathy patients with nondiabetes.

Parameter	Retinopathy patients with nondiabetes
Age (years)	59.1 ±3.2
Male (%)	44.3
Weight (kg)	75.3 ±11.6
Height (cm)	169.8 ±11.1
BMI (kg/m ²)	28.9 ±5.1
Waist (cm)	95.5 ±8.9
SBP (mmHg)	126.3 ±11.6

DBP (mmHg)	79.5 ±9.1
Triglyceride (mg/dL)	148.5±10.6
HDL (mg/dL)	66.3 ±18.1
FPG (mg/dL)	98.7 ±10.5
2hPPG (mg/dL)	189.8±10.5
HbA _{1c} (% (mmol/mol))	5.2±0.6
Smoking (%)	32.1
Drinking (%)	41.8

BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; SBP: systolic blood pressure; SBP: systolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 5. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	<i>p</i> -value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001
Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001

DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001
Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 6. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR* (95% CI)	p-value	OR* (95% CI)	p-value	OR* (95% CI)	p-value	OR* (95% CI)	p-value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60
Diabetes duration	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001

(per 10-year)								
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55
SBP (per 10-mmHg)	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
DBP (per 10-mmHg)	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
Triglycerides (per 10-mg/dL)	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39
HDL cholesterol (per 10-mg/dL)	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
FPG (per 10-mg/dL)	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
2hPPG (per 10-mg/dL)	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
HbA _{1c} (per % (mmol/mol))	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected DM	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-8
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855.R3
Article Type:	Research
Date Submitted by the Author:	28-Aug-2015
Complete List of Authors:	Liu, Lei; The First Affiliated Hospital of China Medical University., ophthalmology Wu, Jingyang; The First Affiliated Hospital of China Medical University., ophthalmology; The First Affiliated Hospital of China Medical University., ophthalmology Yue, Song; The First Affiliated Hospital of China Medical University., ophthalmology Zhang, Jiahua; The First Affiliated Hospital of China Medical University., ophthalmology Lian, Jie; ophthalmology Teng, Weiping; The First Affiliated Hospital of China Medical University., Key Laboratory of Endocrine Diseases in Liaoning Province Huang, Desheng; School of Public Health, China Medical University., Epidemiology Chen, Lei; The First Affiliated Hospital of China Medical University., ophthalmology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Jingyang Wu^{#1}, Song Yue¹, Jiahua Zhang¹, Jie Lian², Weiping Teng³, Desheng Huang^{4*}, Lei Chen^{1,3*}.

Authors` illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3
4 Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,
5

6 P.R. China 110001
7

8
9 Tel: +86-13889378662 Fax:+86-24-83283590
10

11 E-mail: huangdsl@163.com
12

13
14 **Prof. Lei Chen**
15

16
17 Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,
18

19 P.R. China 110122
20

21
22 Tel: +86-13889378662 Fax:+86-24-83282630
23

24 E-mail: carol1422@163.com
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

Design: A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District.

Primary and secondary outcome measures: A total of 1163 eligible participants attended this research. All the participants were took the stereo fundus photography to detect retinopathy. The discrepancy of prevalence for retinopathy in different participants was described.

Results: The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI,1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase).

Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

Strengths and limitations of this study

- It was the first population-based study provided evidence that the relationship between MS and retinopathy in North Chinese population.
- We found that the presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.
- We did not investigate the type of diabetes for all subjects. So the prevalence of retinopathy in diabetes was lower representative.

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with

1
2
3
4 insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It
5
6 is unclear whether the MS is associated with retinopathy in North Chinese population.
7
8
9 The retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were
10
11 differentiated in this study. We examined the cross-sectional association of the MS
12
13 and retinopathy in this population-based study.
14

15 16 **METHODS**

17 18 Study population

19
20
21 This study was carried in Fengyutan health care center which was one of prevention
22
23 models for DR of Liaoning Diabetic Eye center. It is located in Fengyutan
24
25 Sub-District of Shenyang City in North China. There were more than 80,000 residents
26
27 and five communities (including Yutan, Yonghuan, Taoyuan, Qingnian and Zhongxin
28
29 community) in Fengyutan Sub-District, Shenyang, and North China. Firstly, four
30
31 communities were randomly selected from five communities in Fengyutan
32
33 Sub-District. Secondly, 400 households in each of four selected communities were
34
35 randomly chosen according to household register or health files in Fengyutan health
36
37 care center. The participants had lived in Fengyutan for at least two years at the time
38
39 the research was conducted. Then the selected households were informed by
40
41 community officers using message or telephone call. Finally, a total of 1400 subjects,
42
43 aged over 40 years were randomly recruited from August 2013 to September 2014.
44
45
46 After excluding the patients with cancer, hepatic failure, renal failure, severe
47
48 psychiatric disturbance, any other systemic medical condition e.g. severe cardiac
49
50 impairment or severe respiratory impairment, and subjects who did not want to attend
51
52
53
54
55
56
57
58
59
60

1
2
3
4 this study voluntarily, a total of 1163 (response rate 83.07%) eligible participants
5
6 attended this research. Subjects were not attended this study voluntarily or with
7
8 serious illness such as cancer, liver and kidney function failure were excluded.
9

10 11 Data collection

12
13 Information on name, gender, age, smoking, drinking, and health status such as
14
15 duration of diabetes, hypertension duration, past medical history and treatment
16
17 methods were obtained using a standardized questionnaire. In addition, participants
18
19 were asked whether they suffer from DM and if the diagnosis was made by a
20
21 physician. All subjects were also asked to provide information on their current
22
23 medication. Thus, known diabetes was defined according to self-reported physician
24
25 diagnosis or the use of anti-diabetic agents. Following a community office worker
26
27 interview, all participants were asked to fast overnight (>8 hours) before a physical
28
29 examination. Waist circumference was measured at the level of the umbilicus in the
30
31 standing position. Height and weight were measured without wearing hats or heavy
32
33 coats. Blood pressure (BP) was measured in the sitting position (first) and supine
34
35 position (second) at a 5-min interval using an upright standard sphygmomanometer.
36
37 Vigorous physical activity and smoking were avoided for at least 30 min before BP
38
39 measurement. The second BP measurement with the fifth phase diastolic pressure was
40
41 used for analysis. All the participants were took the stereo fundus photography to
42
43 detect retinopathy by 45° Non-Mydriatic Fundus Camera (CR6-45NM, Canon,
44
45 Tokyo, Japan) through undilated pupils. For each subject, two images for each eye
46
47 centered on the fovea and optic disk were taken in the physiologically within a
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 darkened room. Each image was graded in a masked manner by two well-trained
5
6 ophthalmologists separately for the presence of retinopathy lesions. If the grades were
7
8 inconsistent, the other ophthalmologist would give the final diagnosis. The grade of
9
10 retinopathy for each eye was determined and the individual classification was based
11
12 upon the worse eye. There were 41 subjects that could not get a clear retinal image
13
14 because anterior segment opacity. They accepted mydriasis with tropicamide 1%
15
16 (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before 20 minutes of dark adaptation
17
18 and binocular indirect ophthalmoscope by two ophthalmologists who reviewed retinal
19
20 images.
21
22
23
24

25
26 The mayor and the welfare section of Fengyutan Sub-District approved this study. The
27
28 research followed the tenets of the Declaration of Helsinki and informed consent was
29
30 obtained from the subjects after explanation of the nature and possible consequences
31
32 of the study and the research was approved by Institutional Ethics Committee of The
33
34 First Affiliated Hospital of China Medical University.
35
36
37
38

39 Laboratory methods

40
41
42 Blood was drawn from the antecubital vein for determinations of high-density
43
44 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
45
46 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
47
48 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
49
50 (enzymatic assay method) were measured at a commercially available laboratory (The
51
52 Endocrinology Laboratory, China Medical University, and Shenyang, China).
53
54
55

56
57 Definition of MS, retinopathy, smoking, drinking and Diabetes
58
59
60

1
2
3
4 The International Diabetes Federation 2005 (IDF) standards describe a waist
5
6 circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the
7
8 following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid
9
10 abnormality; 2) HDL cholesterol < 1.29 mmol/L or specific treatment for this lipid
11
12 abnormality; 3) raised blood pressure: systolic blood pressure ≥ 130 mmHg or
13
14 diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed
15
16 hypertension; and 4) fasting plasma glucose ≥ 5.6 mmol/L or previously diagnosed
17
18 type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic
19
20 color fundus photographs were graded using the modified Airlie House classification
21
22 and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}
23
24
25
26
27

28 The retinopathy was concerning about diabetic retinopathy except other
29
30 microvascular changes namely vascular dilatation, focal narrowing and other changes.
31
32

33 For each eye, the maximum grade in any of the seven standard photographic fields
34
35 was determined for each of the lesions and used in defining the retinopathy levels.
36
37

38 Drinking was defined as alcohol intake more than once per month during the past 12
39
40 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and
41
42 currently smoking cigarettes.
43
44

45 46 Statistical analyses

47
48 Mean \pm SD was used for measurement data. In univariate analysis, a *t*-test was applied
49
50 for continuous variables and chi-square test (X^2) for nominal-scale data. Independent
51
52 risk factors for retinopathy were analyzed using multiple logistic regressions with
53
54 step-wise approach. Data management and statistical analyses were performed using
55
56
57
58
59
60

1
2
3
4 SPSS statistical software (Version 16.0, SPSS Inc., and Chicago, IL). $P < 0.05$ was
5
6 considered statistically significant.
7

8 9 **RESULTS**

10
11
12 There were 498 subjects with MS. The overall prevalence of MS was 42.82%. Table 1
13
14 showed that demographic data, selected clinical and laboratory findings in patients
15
16 with and without MS.
17

18
19
20 The prevalence for retinopathy was 9.64% ($n=48$) in patients with MS and 3.91%
21
22 ($n=26$) in patients without MS, respectively. Prevalence of retinopathy was
23
24 significantly higher in patients with MS ($p < 0.05$). Table 2 showed that the prevalence
25
26 of proliferative diabetic retinopathy (PDR) was significantly higher in patients with
27
28 MS ($p < 0.05$). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known
29
30 diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had
31
32 retinopathy in Table 3. The characteristics of patients with retinopathy in nondiabetic
33
34 persons were shown in Table 4.
35
36
37
38
39

40
41 Demographic data, selected clinical and laboratory findings in patients with NPDR
42
43 and PDR were shown in Table 5. Patients with NPDR were significantly higher
44
45 prevalence with newly detected diabetes mellitus (DM).
46
47
48

49
50 In multiple logistic regression, independent risk factors for any retinopathy in patients
51
52 with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence
53
54 interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16;
55
56 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24;
57
58
59
60

95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17; 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23; 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS (Table 6).

DISCUSSION

The data reported population-based information regarding the prevalence of MS and its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that the prevalence of the MS was 13.7% in Chinese adult populations. However, the prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that the prevalence of MS was high and might be due to the number of Chinese elder increasing and would be representing a problem of public health in social.

Previous population-based studies in nondiabetic persons have suggested a prevalence of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%). However, another study in China had reported that the prevalence of retinopathy among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban, which may explain partially the lower prevalence found in our study. The overall prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the results of previous meta-analysis in China.²⁶ In our study, the retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were differentiated. Study by Keenan *et al.* showed that the prevalence of retinopathy was 8.6% in patients with MS,

1
2
3
4 and it was little lower than our results. Similarly, the prevalence of retinopathy (3.6%)
5
6 in patients without MS was a slightly lower than that of this study.²⁴
7

8
9 To the best of our knowledge, it was the first population-based study provided
10
11 evidence that the relationship between MS and retinopathy in North Chinese
12
13 population, and MS is an independent risk factor of retinopathy after adjusting age,
14
15 gender and other factors. Previously, a community-based study in South China
16
17 (Shanghai) reported that retinopathy were highly associated with accumulated
18
19 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
20
21 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
22
23 have reported the association between the retinopathy and MS in subjects without
24
25 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
26
27 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
28
29 another study in Japan, a similar association was found.²⁹ Although the researchers in
30
31 these studies did not reveal the relationship between MS and retinopathy in the
32
33 non-diabetic population, it might be due to this cross-sectional study could not
34
35 prevent itself from being with methodological problems. The study design is
36
37 incapable of estimating causal relation directly. In addition, the results of our study
38
39 proved higher prevalence of retinopathy including PDR in patients with MS.
40
41
42 Therefore, we could hypotheses that MS as a risk factor for retinopathy in the subjects,
43
44 and more prospective studies are warranted to determine the significance of the MS
45
46 for predicting risk of retinopathy.
47
48

49
50
51 In this study, we found associations of some individual components of MS with a
52
53
54
55
56
57
58
59
60

1
2
3
4 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
5
6 variables, we also found that no matter the presence of MS or not, as defined by the
7
8 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
9
10 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
11
12 independent risk factors for retinopathy. Higher diastolic blood pressure was the
13
14 independent risk factor for retinopathy in patients with MS. HDL levels was not
15
16 associated with the presence of retinopathy lesions, and some early studies also have
17
18 revealed this conclusion.²⁴ According to our results, we also had not found significant
19
20 association between smoking and drinking in patients with or without MS.
21
22
23
24

25
26 The short coming for this study included it was a population based study in
27
28 community, so there were no fundus fluorescein angiography (FFA), and optical
29
30 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
31
32 in four communities of Shenyang, so there is a selection bias. In addition, we did not
33
34 investigate the type of diabetes for all subjects. So the prevalence of retinopathy in
35
36 diabetes was lower representative.
37
38
39

40 41 CONCLUSION

42
43
44 In summary, our data demonstrate the presence of MS components is significantly
45
46 associated with the prevalence of retinopathy. Rather, in order to prevent retinopathy
47
48 development, risk factors should be controlled in patients with or without MS. More
49
50 comprehensive studies are needed to clarify the roles of MS and also its relationship
51
52 with retinal vascular disorders.
53
54
55

56 57 Acknowledgement

1
2
3
4 Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical
5
6 Editing International, for help in the language editing of this manuscript.
7
8

9 **Contributors:** L. L. and S.Y. and J.H.Z. and J.Y.W and J.L. and W.P.T. researched
10
11 data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited
12
13 the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and
14
15 D.D.H. wrote the manuscript. All authors have given their final approval of this
16
17 manuscript.
18
19

20 21 **Funding**

22
23 This study was funded by National Natural Science Foundation of China (81300783);
24
25 Liaoning Science and Technology Project (2009225005); Liaoning Department of
26
27 Health Medical Peak of Construction Project (2010016); Important Platform of
28
29 Science and Technology for the University in Liaoning Province (16010).
30
31
32
33

34
35 **Competing interests:** None declared.
36

37
38 **Ethics approval:** The study was approved by the Ethics Committee of The First
39
40 Affiliated Hospital Of China Medical University.
41

42
43 **Provenance and peer review:** Not commissioned; externally peer reviewed.
44

45
46 **Data sharing statement:** No additional data are available.
47

48 49 **REFERENCES**

- 50
51 1. Lakka HM, Laaksonen DE, Lakka TA, *et al.* The metabolic syndrome and total and
52
53 cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
54
55
56 2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. J
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Cardiometab Syndr 2007;2:276-82.
3. Feng Y, Hong X, Li Z, *et al*. Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. *Obesity* 2006;14:2089-98.
4. Fang JN, Huang MA, Cui L, *et al*. Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;34:759-61.
5. Golden SH, Folsom AR, Coresh J, *et al*. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002;51:3069-76.
6. Wong TY, Duncan BB, Golden SH, *et al*. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004;45:2949-54.
7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. *Acta Med Indones* 2010;42:187-91.
8. Tung TH, Shih HC, Tsai ST, *et al*. A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;14:148-54.
9. Anan F, Takayuki M, Takahashi N, *et al*. Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. *Hypertens Res* 2009;32:299-305.
10. Zimmet P, Magliano D, Matsuzawa Y, *et al*. The metabolic syndrome: a global

1
2
3
4 public health problem and a new definition. *J Atheroscler Thromb* 2005;12:295-300.

5
6 11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for
7
8 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
9
10 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
11
12 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.
13
14 *Diabetes Res Clin Pract* 1999;44:21-6.

15
16
17 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
18
19 retinopathy from stereoscopic color fundus photographs--an extension of the modified
20
21 Airlie House classification. ETDRS report number 10. *Ophthalmology*
22
23 1991;98:786-806.

24
25
26 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
27
28 photographic risk factors for progression of diabetic retinopathy. ETDRS report
29
30 number 12. *Ophthalmology* 1991;98:823-33.

31
32
33 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
34
35 in a large professional population in Beijing. *Atherosclerosis* 2006;184:188-92.

36
37
38 15. Gu D, Reynolds K, Wu X, *et al.* Prevalence of the metabolic syndrome and
39
40 overweight among adults in China. *Lancet* 2005;365:1398-405.

41
42
43 16. He Y, Jiang B, Wang J, *et al.* Prevalence of the metabolic syndrome and its
44
45 relation to cardiovascular disease in an elderly Chinese population. *J Am Coll Cardiol*
46
47 2006;47:1588-94.

48
49
50 17. Klein R, Klein BE, Moss SE, *et al.* Hypertension and retinopathy, arteriolar
51
52

- 1
2
3
4 narrowing, and arteriovenous nicking in a population. Arch Ophthalmol
5
6 1994;112:92-8.
7
8
9 18. Yu T, Mitchell P, Berry G, *et al.* Retinopathy in older persons without diabetes and
10
11 its relationship to hypertension. Arch Ophthalmol 1998;116:83-9.
12
13
14 19. Hubbard LD, Brothers RJ, King WN, *et al.* Methods for evaluation of retinal
15
16 microvascular abnormalities associated with hypertension/sclerosis in the
17
18 Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269-80.
19
20
21 20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated
22
23 with retinopathy: the Hoorn Study. Diabetes Care 2002;25:1320-5.
24
25
26 21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal
27
28 microvascular abnormalities in older persons: the Cardiovascular Health Study.
29
30 Ophthalmology 2003;110:658-66.
31
32
33 22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated
34
35 with diabetic retinopathy in the Australian population. Diabetes Care 2003;26:1731-7.
36
37
38 23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal
39
40 microvascular signs in an adult Japanese population: the Funagata Study.
41
42 Ophthalmology 2006;113:1378-84.
43
44
45 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
46
47 metabolic syndrome: findings from the Third National Health and Nutrition
48
49 Examination Survey. Am J Ophthalmol. 2009;147:934-44, 944.e1-2.
50
51
52 25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes: the
53
54
55
56
57
58
59
60

Handan Eye Study. *Ophthalmology* 2010;117:531-7, 537.e1-2.

26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China: a meta-analysis. *PLoS One* 2012;7:e45264.

27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular diseases in Chinese community-based subjects with various metabolic abnormalities. *PLoS One* 2014;9:e97928.

28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic syndrome and diabetic microangiopathy. *Exp Ther Med* 2014;8:1867-73.

29. Kawasaki R, Tielsch JM, Wang JJ, *et al.* The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol* 2008;92:161-6.

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS (<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001
Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001
DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001

Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (n=48)	Without MS (n=26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

Table 3. Prevalence of retinopathy in different groups of this study.

Item	Retinopathy (n)	Prevalence (%)
Total diabetes	55	11.79
Known diabetes	34	18.18
Newly detected diabetes	21	7.72
Non-diabetes	19	3.25
With MS	48	9.64
Without MS	26	3.91
Total subjects	74	6.36

MS: metabolic syndrome.

Table 4. Demographic data, selected clinical and laboratory findings in retinopathy patients with nondiabetes.

Parameter	Retinopathy patients with nondiabetes
Age (years)	59.1 ±3.2
Male (%)	44.3
Weight (kg)	75.3 ±11.6
Height (cm)	169.8 ±11.1
BMI (kg/m ²)	28.9 ±5.1
Waist (cm)	95.5 ±8.9
SBP (mmHg)	126.3 ±11.6
DBP (mmHg)	79.5 ±9.1
Triglyceride (mg/dL)	148.5±10.6
HDL (mg/dL)	66.3 ±18.1
FPG (mg/dL)	98.7 ±10.5
2hPPG (mg/dL)	189.8±10.5
HbA _{1c} (% (mmol/mol))	5.2±0.6

Smoking (%)	32.1
Drinking (%)	41.8

BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; SBP: systolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 5. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	p-value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001
Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001
DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001

Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 6. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value	OR ^a (95% CI)	<i>p</i> -value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60
Diabetes duration (per 10-year)	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55

10-cm)								
SBP (per	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
10-mmHg)								
DBP (per	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
10-mmHg)								
Triglycerides (per	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39
10-mg/dL)								
HDL cholesterol	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
(per 10-mg/dL)								
FPG (per	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
10-mg/dL)								
2hPPG (per	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
10-mg/dL)								
HbA _{1c} (per %	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
(mmol/mol))								
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35
DM								

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-8
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855.R4
Article Type:	Research
Date Submitted by the Author:	17-Sep-2015
Complete List of Authors:	Liu, Lei; The First Affiliated Hospital of China Medical University., ophthalmology Wu, Jingyang; The First Affiliated Hospital of China Medical University., ophthalmology; The First Affiliated Hospital of China Medical University., ophthalmology Yue, Song; The First Affiliated Hospital of China Medical University., ophthalmology Zhang, Jiahua; The First Affiliated Hospital of China Medical University., ophthalmology Lian, Jie; ophthalmology Teng, Weiping; The First Affiliated Hospital of China Medical University., Key Laboratory of Endocrine Diseases in Liaoning Province Huang, Desheng; School of Public Health, China Medical University., Epidemiology Chen, Lei; The First Affiliated Hospital of China Medical University., ophthalmology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Jingyang Wu^{#1}, Song Yue¹, Jiahua Zhang¹, Jie Lian², Weiping Teng³, Desheng Huang^{4*}, Lei Chen^{1,3*}.

Authors' illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3 Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,
4
5

6 P.R. China 110001
7

8
9 Tel: +86-13889378662 Fax:+86-24-83283590
10

11 E-mail: huangdsll@163.com
12
13

14 **Prof. Lei Chen**
15

16
17 Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,
18

19 P.R. China 110122
20

21
22 Tel: +86-13889378662 Fax:+86-24-83282630
23

24 E-mail: carol1422@163.com
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

Design: A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District.

Primary and secondary outcome measures: A total of 1163 eligible participants attended this research. All the participants were took the stereo fundus photography to detect retinopathy. The discrepancy of prevalence for retinopathy in different participants was described.

Results: The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI,1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase).

Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

Strengths and limitations of this study

- It was the first population-based study provided evidence that the relationship between MS and retinopathy in North Chinese population.
- We found that the presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.
- We did not investigate the type of diabetes for all subjects. So the prevalence of retinopathy in diabetes was lower representative.

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with

1
2
3
4 insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It
5
6 is unclear whether the MS is associated with retinopathy in North Chinese population.
7
8
9 The retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were
10
11 differentiated in this study. We examined the cross-sectional association of the MS
12
13 and retinopathy in this population-based study.
14

15 16 **METHODS**

17 18 Study population

19
20
21 This study was carried in Fengyutan health care center which was one of prevention
22
23 models for DR of Liaoning Diabetic Eye center. It is located in Fengyutan
24
25 Sub-District of Shenyang City in North China. There were more than 80,000 residents
26
27 and five communities (including Yutan, Yonghuan, Taoyuan, Qingnian and Zhongxin
28
29 community) in Fengyutan Sub-District, Shenyang, and North China. A multistage,
30
31 stratified random sampling was carried for selection of residents. Firstly, four
32
33 communities were randomly selected from five communities in Fengyutan
34
35 Sub-District. Secondly, 400 households in each of four selected communities were
36
37 randomly chosen according to household register or health files in Fengyutan health
38
39 care center. So there would be 1600 households in our study totally. The participants
40
41 had lived in Fengyutan for at least two years at the time the research was conducted.
42
43
44 Then the selected households were informed by community officers using message or
45
46 telephone call. Except the subjects who could not be contacted, a total of 1400
47
48
49 subjects, aged over 40 years were randomly recruited from August 2013 to September
50
51
52 2014. After excluding the patients with cancer, hepatic failure, renal failure, severe
53
54
55
56
57
58
59
60

1
2
3
4 psychiatric disturbance, any other systemic medical condition e.g. severe cardiac
5
6 impairment or severe respiratory impairment, and subjects who did not want to attend
7
8 this study voluntarily, a total of 1163 eligible participants attended this research.
9
10
11 Subjects were not attended this study voluntarily or with serious illness such as cancer,
12
13 liver and kidney function failure were excluded.
14

15 16 Data collection

17
18 Information on name, gender, age, smoking, drinking, and health status such as
19
20 duration of diabetes, hypertension duration, past medical history and treatment
21
22 methods were obtained using a standardized questionnaire. In addition, participants
23
24 were asked whether they suffer from DM and if the diagnosis was made by a
25
26 physician. All subjects were also asked to provide information on their current
27
28 medication. Thus, known diabetes was defined according to self-reported physician
29
30 diagnosis or the use of anti-diabetic agents. Following a community office worker
31
32 interview, all participants were asked to fast overnight (>8 hours) before a physical
33
34 examination. Waist circumference was measured at the level of the umbilicus in the
35
36 standing position. Height and weight were measured without wearing hats or heavy
37
38 coats. Blood pressure (BP) was measured in the sitting position (first) and supine
39
40 position (second) at a 5-min interval using an upright standard sphygmomanometer.
41
42 Vigorous physical activity and smoking were avoided for at least 30 min before BP
43
44 measurement. The second BP measurement with the fifth phase diastolic pressure was
45
46 used for analysis. All the participants were took the stereo fundus photography to
47
48 detect retinopathy by 45° Non-Mydriatic Fundus Camera (CR6-45NM, Canon,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Tokyo, Japan) through undilated pupils. For each subject, two images for each eye
5
6 centered on the fovea and optic disk were taken in the physiologically within a
7
8 darkened room. Each image was graded in a masked manner by two well-trained
9
10 ophthalmologists separately for the presence of retinopathy lesions. If the grades were
11
12 inconsistent, the other ophthalmologist would give the final diagnosis. The grade of
13
14 retinopathy for each eye was determined and the individual classification was based
15
16 upon the worse eye. There were 41 subjects that could not get a clear retinal image
17
18 because anterior segment opacity. They accepted mydriasis with tropicamide 1%
19
20 (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before 20 minutes of dark adaptation
21
22 and binocular indirect ophthalmoscope by two ophthalmologists who reviewed retinal
23
24 images.
25
26
27
28
29

30
31 The mayor and the welfare section of Fengyutan Sub-District approved this study. The
32
33 research followed the tenets of the Declaration of Helsinki and informed consent was
34
35 obtained from the subjects after explanation of the nature and possible consequences
36
37 of the study and the research was approved by Institutional Ethics Committee of The
38
39 First Affiliated Hospital of China Medical University. All subjects provided their
40
41 written informed consent.
42
43
44
45

46 47 Laboratory methods

48
49 Blood was drawn from the antecubital vein for determinations of high-density
50
51 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
52
53 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
54
55 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
56
57
58
59
60

(enzymatic assay method) were measured at a commercially available laboratory (The Endocrinology Laboratory, China Medical University, and Shenyang, China).

Definition of MS, retinopathy, smoking, drinking and Diabetes

The International Diabetes Federation 2005 (IDF) standards describe a waist circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid abnormality; 2) HDL cholesterol < 1.29 mmol/L or specific treatment for this lipid abnormality; 3) raised blood pressure: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension; and 4) fasting plasma glucose ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic color fundus photographs were graded using the modified Airlie House classification and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}

The retinopathy was concerning about diabetic retinopathy except other microvascular changes namely vascular dilatation, focal narrowing and other changes.

For each eye, the maximum grade in any of the seven standard photographic fields was determined for each of the lesions and used in defining the retinopathy levels.

Drinking was defined as alcohol intake more than once per month during the past 12 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and currently smoking cigarettes.

Statistical analyses

Mean \pm SD was used for measurement data. In univariate analysis, a *t*-test was applied

1
2
3
4 for continuous variables and chi-square test (χ^2) for nominal-scale data. Independent
5
6 risk factors for retinopathy were analyzed using multiple logistic regressions with
7
8 step-wise approach. Data management and statistical analyses were performed using
9
10 SPSS statistical software (Version 16.0, SPSS Inc., and Chicago, IL). $P < 0.05$ was
11
12 considered statistically significant.
13
14

15 16 **RESULTS**

17
18
19 The response rate was 83.07% (1163/1400) in this survey. There were 498 subjects
20
21 with MS. The overall prevalence of MS was 42.82%. Table 1 showed that
22
23 demographic data, selected clinical and laboratory findings in patients with and
24
25 without MS.
26
27

28
29
30 The prevalence for retinopathy was 9.64% (n=48) in patients with MS and 3.91%
31
32 (n=26) in patients without MS, respectively. Prevalence of retinopathy was
33
34 significantly higher in patients with MS ($p < 0.05$). Table 2 showed that the prevalence
35
36 of proliferative diabetic retinopathy (PDR) was significantly higher in patients with
37
38 MS ($p < 0.05$). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known
39
40 diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had
41
42 retinopathy in Table 3. The characteristics of patients with retinopathy in nondiabetic
43
44 persons were shown in Table 4.
45
46
47

48
49
50 Demographic data, selected clinical and laboratory findings in patients with NPDR
51
52 and PDR were shown in Table 5. Patients with NPDR were significantly higher
53
54 prevalence with newly detected diabetes mellitus (DM).
55
56
57
58
59
60

1
2
3
4 In multiple logistic regression, independent risk factors for any retinopathy in patients
5
6 with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence
7
8 interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16;
9
10 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24;
11
12 95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95%
13
14 CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17;
15
16 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23;
17
18 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP,
19
20 were found for any retinopathy in patients without MS (Table 6).
21
22
23
24

25 26 **DISCUSSION**

27
28 The data reported population-based information regarding the prevalence of MS and
29
30 its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF
31
32 criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that
33
34 the prevalence of the MS was 13.7% in Chinese adult populations. However, the
35
36 prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that
37
38 the prevalence of MS was high and might be due to the number of Chinese elder
39
40 increasing and would be representing a problem of public health in social.
41
42
43
44

45
46 Previous population-based studies in nondiabetic persons have suggested a prevalence
47
48 of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%).
49
50 However, another study in China had reported that the prevalence of retinopathy
51
52 among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban,
53
54 which may explain partially the lower prevalence found in our study. The overall
55
56
57
58
59
60

1
2
3
4 prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the
5
6 results of previous meta-analysis in China.²⁶ In our study, the retinopathy secondary to
7
8 MS and retinopathy secondary to diabetes mellitus were differentiated. Study by
9
10 Keenan *et al.* showed that the prevalence of retinopathy was 8.6% in patients with MS,
11
12 and it was little lower than our results. Similarly, the prevalence of retinopathy (3.6%)
13
14 in patients without MS was a slightly lower than that of this study.²⁴
15
16
17 To the best of our knowledge, it was the first population-based study provided
18
19 evidence that the relationship between MS and retinopathy in North Chinese
20
21 population, and MS is an independent risk factor of retinopathy after adjusting age,
22
23 gender and other factors. Previously, a community-based study in South China
24
25 (Shanghai) reported that retinopathy were highly associated with accumulated
26
27 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
28
29 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
30
31 have reported the association between the retinopathy and MS in subjects without
32
33 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
34
35 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
36
37 another study in Japan, a similar association was found.²⁹ Although the researchers in
38
39 these studies did not reveal the relationship between MS and retinopathy in the
40
41 non-diabetic population, it might be due to this cross-sectional study could not
42
43 prevent itself from being with methodological problems. The study design is
44
45 incapable of estimating causal relation directly. In addition, the results of our study
46
47 proved higher prevalence of retinopathy including PDR in patients with MS.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Therefore, we could hypothesises that MS as a risk factor for retinopathy in the subjects,
5
6 and more prospective studies are warranted to determine the significance of the MS
7
8 for predicting risk of retinopathy.
9

10
11 In this study, we found associations of some individual components of MS with a
12
13 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
14
15 variables, we also found that no matter the presence of MS or not, as defined by the
16
17 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
18
19 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
20
21 independent risk factors for retinopathy. Higher diastolic blood pressure was the
22
23 independent risk factor for retinopathy in patients with MS. HDL levels was not
24
25 associated with the presence of retinopathy lesions, and some early studies also have
26
27 revealed this conclusion.²⁴ According to our results, we also had not found significant
28
29 association between smoking and drinking in patients with or without MS.
30
31

32
33 The short coming for this study included it was a population based study in
34
35 community, so there were no fundus fluorescein angiography (FFA), and optical
36
37 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
38
39 in four communities of Shenyang, so there is a selection bias. In addition, we did not
40
41 investigate the type of diabetes for all subjects. So the prevalence of retinopathy in
42
43 diabetes was lower representative.
44
45
46
47
48
49

50 51 CONCLUSION

52
53 In summary, our data demonstrate the presence of MS components is significantly
54
55 associated with the prevalence of retinopathy. Rather, in order to prevent retinopathy
56
57
58
59
60

1
2
3
4 development, risk factors should be controlled in patients with or without MS. More
5
6 comprehensive studies are needed to clarify the roles of MS and also its relationship
7
8 with retinal vascular disorders.
9

10 11 **Acknowledgement**

12
13
14 Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical
15
16 Editing International, for help in the language editing of this manuscript.
17

18
19 **Contributors:** L. L. and S.Y. and J.H.Z. and J.Y.W and J.L. and W.P.T. researched
20
21 data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited
22
23 the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and
24
25 D.D.H. wrote the manuscript. All authors have given their final approval of this
26
27 manuscript.
28
29

30 31 **Funding**

32
33 This study was funded by National Natural Science Foundation of China (81300783);
34
35 Liaoning Science and Technology Project (2009225005); Liaoning Department of
36
37 Health Medical Peak of Construction Project (2010016); Important Platform of
38
39 Science and Technology for the University in Liaoning Province (16010).
40
41
42
43

44
45 **Competing interests:** No, there are no competing interests.
46
47

48
49 **Ethics approval:** The study was approved by the Ethics Committee of The First
50
51 Affiliated Hospital Of China Medical University.
52

53
54 **Provenance and peer review:** Not commissioned; externally peer reviewed.
55

56
57 **Data sharing statement:** No additional data are available.
58
59
60

REFERENCES

1. Lakka HM, Laaksonen DE, Lakka TA, *et al*. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-16.
2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. *J Cardiometab Syndr* 2007;2:276-82.
3. Feng Y, Hong X, Li Z, *et al*. Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. *Obesity* 2006;14:2089-98.
4. Fang JN, Huang MA, Cui L, *et al*. Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;34:759-61.
5. Golden SH, Folsom AR, Coresh J, *et al*. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002;51:3069-76.
6. Wong TY, Duncan BB, Golden SH, *et al*. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004;45:2949-54.
7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. *Acta Med Indones* 2010;42:187-91.
8. Tung TH, Shih HC, Tsai ST, *et al*. A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;14:148-54.

- 1
2
3
4 9. Anan F, Takayuki M, Takahashi N, *et al.* Diabetic retinopathy is associated with
5
6 insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic
7
8 patients. *Hypertens Res* 2009;32:299-305.
9
10
11 10. Zimmet P, Magliano D, Matsuzawa Y, *et al.* The metabolic syndrome: a global
12
13 public health problem and a new definition. *J Atheroscler Thromb* 2005;12:295-300.
14
15
16 11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for
17
18 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
19
20 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
21
22 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.
23
24
25
26
27
28
29
30 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
31
32 retinopathy from stereoscopic color fundus photographs--an extension of the modified
33
34 Airlie House classification. ETDRS report number 10. *Ophthalmology*
35
36 1991;98:786-806.
37
38
39
40 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
41
42 photographic risk factors for progression of diabetic retinopathy. ETDRS report
43
44 number 12. *Ophthalmology* 1991;98:823-33.
45
46
47
48 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
49
50 in a large professional population in Beijing. *Atherosclerosis* 2006;184:188-92.
51
52
53 15. Gu D, Reynolds K, Wu X, *et al.* Prevalence of the metabolic syndrome and
54
55 overweight among adults in China. *Lancet* 2005;365:1398-405.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. He Y, Jiang B, Wang J, *et al.* Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. *J Am Coll Cardiol* 2006;47:1588-94.
17. Klein R, Klein BE, Moss SE, *et al.* Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol* 1994;112:92-8.
18. Yu T, Mitchell P, Berry G, *et al.* Retinopathy in older persons without diabetes and its relationship to hypertension. *Arch Ophthalmol* 1998;116:83-9.
19. Hubbard LD, Brothers RJ, King WN, *et al.* Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. *Ophthalmology* 1999;106:2269-80.
20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated with retinopathy: the Hoorn Study. *Diabetes Care* 2002;25:1320-5.
21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal microvascular abnormalities in older persons: the Cardiovascular Health Study. *Ophthalmology* 2003;110:658-66.
22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated with diabetic retinopathy in the Australian population. *Diabetes Care* 2003;26:1731-7.
23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population: the Funagata Study. *Ophthalmology* 2006;113:1378-84.

- 1
2
3
4 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
5
6 metabolic syndrome: findings from the Third National Health and Nutrition
7
8 Examination Survey. *Am J Ophthalmol.* 2009;147:934-44, 944.e1-2.
9
10
11 25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes: the
12
13 Handan Eye Study. *Ophthalmology* 2010;117:531-7, 537.e1-2.
14
15
16 26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China: a
17
18 meta-analysis. *PLoS One* 2012;7:e45264.
19
20
21 27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular
22
23 diseases in Chinese community-based subjects with various metabolic abnormalities.
24
25 *PLoS One* 2014;9:e97928.
26
27
28 28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic
29
30 syndrome and diabetic microangiopathy. *Exp Ther Med* 2014;8:1867-73.
31
32
33 29. Kawasaki R, Tielsch JM, Wang JJ, *et al.* The metabolic syndrome and retinal
34
35 microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol*
36
37 2008;92:161-6.
38
39
40
41
42
43
44
45
46
47
48
49
50

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS (<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001

Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001
DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001
Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (n=48)	Without MS (n=26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

Table 3. Prevalence of retinopathy in different groups of this study.

Item	Retinopathy (n)	Prevalence (%)
Total diabetes	55	11.79
Known diabetes	34	18.18
Newly detected diabetes	21	7.72
Non-diabetes	19	3.25
With MS	48	9.64
Without MS	26	3.91
Total subjects	74	6.36

MS: metabolic syndrome.

Table 4. Demographic data, selected clinical and laboratory findings in retinopathy patients with nondiabetes.

Parameter	Retinopathy patients with nondiabetes
Age (years)	59.1 ±3.2
Male (%)	44.3
Weight (kg)	75.3 ±11.6
Height (cm)	169.8 ±11.1
BMI (kg/m ²)	28.9 ±5.1

Waist (cm)	95.5 ±8.9
SBP (mmHg)	126.3 ±11.6
DBP (mmHg)	79.5 ±9.1
Triglyceride (mg/dL)	148.5±10.6
HDL (mg/dL)	66.3 ±18.1
FPG (mg/dL)	98.7 ±10.5
2hPPG (mg/dL)	189.8±10.5
HbA _{1c} (% (mmol/mol))	5.2±0.6
Smoking (%)	32.1
Drinking (%)	41.8

BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; SBP: systolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 5. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	<i>p</i> -value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001

Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001
DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001
Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 6. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR [#] (95% CI)	<i>p</i> -value	OR [#] (95% CI)	<i>p</i> -value	OR [#] (95% CI)	<i>p</i> -value	OR [#] (95% CI)	<i>p</i> -value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60

)								
Diabetes duration (per 10-year)	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55
SBP (per 10-mmHg)	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
DBP (per 10-mmHg)	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
Triglycerides (per 10-mg/dL)	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39
HDL cholesterol (per 10-mg/dL)	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
FPG (per 10-mg/dL)	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
2hPPG (per 10-mg/dL)	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
HbA _{1c} (per % (mmol/mol))	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected DM	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-8
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008855.R5
Article Type:	Research
Date Submitted by the Author:	21-Oct-2015
Complete List of Authors:	Liu, Lei; The First Affiliated Hospital of China Medical University., ophthalmology Yue, Song; The First Affiliated Hospital of China Medical University., ophthalmology Wu, Jingyang; The First Affiliated Hospital of China Medical University., ophthalmology; The First Affiliated Hospital of China Medical University., ophthalmology Zhang, Jiahua; The First Affiliated Hospital of China Medical University., ophthalmology Lian, Jie; Fengyutan Sub-District, Healthcenter Teng, Weiping; The First Affiliated Hospital of China Medical University., Key Laboratory of Endocrine Diseases in Liaoning Province Huang, Desheng; School of Public Health, China Medical University., Epidemiology Chen, Lei; The First Affiliated Hospital of China Medical University., ophthalmology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Ophthalmology
Keywords:	DIABETES & ENDOCRINOLOGY, Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

TITLE PAGE**Title:**

Prevalence and risk factors of retinopathy in patients with or without Metabolic Syndrome– A population-based study in Shenyang.

Running title: Prevalence and risk factors of retinopathy in MS

All authors: Lei Liu^{#1}, Song Yue^{#1}, Jingyang Wu¹, Jiahua Zhang¹, Jie Lian², Weiping Teng³, Desheng Huang^{4*}, Lei Chen^{1,3*}.

Authors' illustration:

1. Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, China.
2. Department of Healthcenter, Fengyutan Sub-District, Shenyang, China.
3. Key Laboratory of Endocrine Diseases in Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
4. Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.

[#]These authors contributed to the work equally and should be regarded as co-first authors.

^{*}These authors were both Corresponding Authors.

Corresponding Author's information:

Prof. Desheng Huang OR Prof. Lei Chen

Prof. Desheng Huang

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Address: No.77 Puhe Road,Shenyang North New Area, Shenyang, Liaoning Province,

P.R. China 110001

Tel: +86-13889378662 Fax:+86-24-83283590

E-mail: huangdsll@163.com

Prof. Lei Chen

Address: No. 155 Nanjing North Street, Heping district, Shenyang, Liaoning Province,

P.R. China 110122

Tel: +86-13889378662 Fax:+86-24-83282630

E-mail: carol1422@163.com

ABSTRACT

Objectives: To investigate the relationship between metabolic syndrome (MS) and prevalence of retinopathy.

Design: A cross-section study was carried out from August 2013 to September 2014 in Fengyutan Sub-District.

Primary and secondary outcome measures: A total of 1163 eligible participants attended this research. All the participants were took the stereo fundus photography to detect retinopathy. The discrepancy of prevalence for retinopathy in different participants was described.

Results: The prevalence for retinopathy was 9.64% in patients with MS and 3.91% in patients without MS. Also higher prevalence of retinopathy with proliferative diabetic retinopathy (PDR) was found in patients with MS. In multiple logistic regression, independent risk factors for any retinopathy in patients with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% CI, 1.04-1.10, per year increase), higher systolic blood pressure (SBP) (OR, 1.16; 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (DBP) (OR, 1.24; 95% CI, 1.12-1.35, per-10mmHg increase), higher fasting plasma glucose (OR, 1.17; 95% CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.07; 95% CI,1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34, per % increase).

Similar independent risk factors, except for DBP, were found for any retinopathy in patients without MS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions: The presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.

Keywords: Metabolic syndrome; Prevalence; Retinopathy; Risk factor.

Strengths and limitations of this study

- It was the first population-based study provided evidence that the relationship between MS and retinopathy in North Chinese population.
- We found that the presence of MS components hyperglycemia (fasting glucose and HbA1c) and hypertension (SBP and DBP) are significantly associated with the prevalence of retinopathy.
- We did not investigate the type of diabetes for all subjects. So the prevalence of retinopathy in diabetes was lower representative.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

INTRODUCTION

Metabolic syndrome (MS) is a cluster of metabolic disorders characterized by abdominal obesity, hyperglycemia, hyperlipidemia, and hypertension.¹ Insulin resistance has been proposed to be of key pathogenetic importance. The prevalence of MS is increasing East Asian countries including China, leading to increased morbidity and mortality due to type 2 diabetic mellitus (DM) and cardiovascular disease (CVD).² The MS is increasingly recognized as being a distinct entity affecting a large proportion of the Chinese population.^{3,4} Patients with the MS are at known risk of development of large-vessel diseases and retinal microvascular abnormalities.^{5,6} Some combinations of traits of MS may significantly contribute to identify subjects with insulin resistance.⁷ Insulin resistance is a risk factor for diabetic retinopathy (DR).^{8,9} It is unclear whether the MS is associated with retinopathy in North Chinese population. The retinopathy secondary to MS and retinopathy secondary to diabetes mellitus were differentiated in this study. We examined the cross-sectional association of the MS and retinopathy in this population-based study.

METHODS

Study population

This study was carried in Fengyutan health care center which was one of prevention models for DR of Liaoning Diabetic Eye center. It is located in Fengyutan Sub-District of Shenyang City in North China. There were more than 80,000 residents and five communities (including Yutan, Yonghuan, Taoyuan, Qingnian and Zhongxin community) in Fengyutan Sub-District, Shenyang, and North China. A multistage,

1
2
3
4 stratified random sampling was carried for selection of residents. Firstly, those five
5
6 communities were numbered. Then four communities were randomly selected from
7
8 five numbers. Secondly, the household register or health files in Fengyutan health care
9
10 center were numbered, and 400 households in each of four selected communities were
11
12 randomly chosen using “True Random Number Generator”
13
14 (<https://www.random.org/>). The participants had lived in Fengyutan for at least two
15
16 years at the time the research was conducted. Then the selected households were
17
18 informed by community officers using message or telephone call. Finally, a total of
19
20 1400 subjects, aged over 40 years attended this study from August 2013 to September
21
22 2014. After excluding the patients with cancer, hepatic failure, renal failure, severe
23
24 psychiatric disturbance, any other systemic medical condition e.g. severe cardiac
25
26 impairment or severe respiratory impairment, and subjects who did not want to attend
27
28 this study voluntarily, a total of 1163 (response rate 83.07%) eligible participants
29
30 attended this research. Subjects were not attended this study voluntarily or with
31
32 serious illness such as cancer, liver and kidney function failure were excluded.
33
34
35
36
37
38
39
40

41 Data collection

42
43 Information on name, gender, age, smoking, drinking, and health status such as
44
45 duration of diabetes, hypertension duration, past medical history and treatment
46
47 methods were obtained using a standardized questionnaire. In addition, participants
48
49 were asked whether they suffer from DM and if the diagnosis was made by a
50
51 physician. All subjects were also asked to provide information on their current
52
53 medication. Thus, known diabetes was defined according to self-reported physician
54
55
56
57
58
59
60

1
2
3
4 diagnosis or the use of anti-diabetic agents. Following a community office worker
5
6 interview, all participants were asked to fast overnight (>8 hours) before a physical
7
8 examination. Waist circumference was measured at the level of the umbilicus in the
9
10 standing position. Height and weight were measured without wearing hats or heavy
11
12 coats. Blood pressure (BP) was measured in the sitting position (first) and supine
13
14 position (second) at a 5-min interval using an upright standard sphygmomanometer.
15
16 Vigorous physical activity and smoking were avoided for at least 30 min before BP
17
18 measurement. The second BP measurement with the fifth phase diastolic pressure was
19
20 used for analysis. All the participants were took the stereo fundus photography to
21
22 detect retinopathy by 45° Non-Mydriatic Fundus Camera (CR6-45NM, Canon,
23
24 Tokyo, Japan) through undilated pupils. For each subject, two images for each eye
25
26 centered on the fovea and optic disk were taken in the physiologically within a
27
28 darkened room. Each image was graded in a masked manner by two well-trained
29
30 ophthalmologists separately for the presence of retinopathy lesions. If the grades were
31
32 inconsistent, the other ophthalmologist would give the final diagnosis. The grade of
33
34 retinopathy for each eye was determined and the individual classification was based
35
36 upon the worse eye. There were 41 subjects that could not get a clear retinal image
37
38 because anterior segment opacity. They accepted mydriasis with tropicamide 1%
39
40 (Santen Pharmaceutical Co.,Ltd. Shiga, Japan) before 20 minutes of dark adaptation
41
42 and binocular indirect ophthalmoscope by two ophthalmologists who reviewed retinal
43
44 images.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The mayor and the welfare section of Fengyutan Sub-District approved this study. The

1
2
3
4 research followed the tenets of the Declaration of Helsinki and informed consent was
5
6 obtained from the subjects after explanation of the nature and possible consequences
7
8 of the study and the research was approved by Institutional Ethics Committee of The
9
10 First Affiliated Hospital of China Medical University.
11
12

13 14 Laboratory methods

15
16 Blood was drawn from the antecubital vein for determinations of high-density
17
18 lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose levels, and
19
20 hemoglobin A_{1c} in the morning after 8 hours fast. Then 75-g oral glucose tolerance
21
22 test (OGTT) would be done, 2 hours later blood was drawn again. All chemistries
23
24 (enzymatic assay method) were measured at a commercially available laboratory (The
25
26 Endocrinology Laboratory, China Medical University, and Shenyang, China).
27
28
29
30
31

32 Definition of MS, retinopathy, smoking, drinking and Diabetes

33
34 The International Diabetes Federation 2005 (IDF) standards describe a waist
35
36 circumference for Chinese female of ≥ 80 cm and male of ≥ 90 cm plus 2 or more of the
37
38 following 4 risk factors: 1) TG ≥ 1.70 mmol/L or specific treatment for this lipid
39
40 abnormality; 2) HDL cholesterol < 1.29 mmol/L or specific treatment for this lipid
41
42 abnormality; 3) raised blood pressure: systolic blood pressure ≥ 130 mmHg or
43
44 diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed
45
46 hypertension; and 4) fasting plasma glucose ≥ 5.6 mmol/L or previously diagnosed
47
48 type 2 diabetes.¹⁰ Diabetes diagnosed according to 1999 WHO criteria.¹¹ Stereoscopic
49
50 color fundus photographs were graded using the modified Airlie House classification
51
52 and the Early Treatment Diabetic Retinopathy Study retinopathy severity scheme.^{12,13}
53
54
55
56
57
58
59
60

1
2
3
4 The retinopathy was concerning about diabetic retinopathy except other
5
6 microvascular changes namely vascular dilatation, focal narrowing and other changes.
7
8
9 For each eye, the maximum grade in any of the seven standard photographic fields
10
11 was determined for each of the lesions and used in defining the retinopathy levels.
12
13
14 Drinking was defined as alcohol intake more than once per month during the past 12
15
16 months. Smoking was defined as having smoked 100 cigarettes in one's lifetime and
17
18 currently smoking cigarettes.
19

20 21 Statistical analyses

22
23
24 Mean±SD was used for measurement data. In univariate analysis, a *t*-test was applied
25
26 for continuous variables and chi-square test (X^2) for nominal-scale data. Independent
27
28 risk factors for retinopathy were analyzed using multiple logistic regressions with
29
30 step-wise approach. Data management and statistical analyses were performed using
31
32 SPSS statistical software (Version 16.0, SPSS Inc., and Chicago, IL). $P<0.05$ was
33
34 considered statistically significant.
35
36
37

38 39 **RESULTS**

40
41
42 There were 498 subjects with MS. The overall prevalence of MS was 42.82%. Table 1
43
44 showed that demographic data, selected clinical and laboratory findings in patients
45
46 with and without MS.
47
48

49
50 The prevalence for retinopathy was 9.64% (n=48) in patients with MS and 3.91%
51
52 (n=26) in patients without MS, respectively. Prevalence of retinopathy was
53
54 significantly higher in patients with MS ($p<0.05$). Table 2 showed that the prevalence
55
56
57
58
59
60

1
2
3
4 of proliferative diabetic retinopathy (PDR) was significantly higher in patients with
5
6 MS ($p < 0.05$). In addition, 6.36% of all persons, 11.79% of diabetes, 18.18% of known
7
8 diabetes, 7.72% of newly detected diabetes and 3.25% of nondiabetic persons had
9
10 retinopathy in Table 3. The characteristics of patients with retinopathy in nondiabetic
11
12 persons were shown in Table 4.

13
14
15
16
17 Demographic data, selected clinical and laboratory findings in patients with NPDR
18
19 and PDR were shown in Table 5. Patients with NPDR were significantly higher
20
21 prevalence with newly detected diabetes mellitus (DM).

22
23
24
25
26 In multiple logistic regression, independent risk factors for any retinopathy in patients
27
28 with MS were longer diabetes duration (odds ratio (OR), 1.07; 95% confidence
29
30 interval (CI), 1.04-1.10, per year increase), higher systolic blood pressure (OR, 1.16;
31
32 95% CI, 1.09-1.29, per -10mmHg increase), higher diastolic blood pressure (OR, 1.24;
33
34 95% CI, 1.12-1.35, per -10mmHg increase), higher plasma glucose (OR, 1.07; 95%
35
36 CI, 1.02-1.11, per-10 mg/dL increase), 2h-postprandial plasma glucose (OR, 1.17;
37
38 95% CI, 1.12-1.21, per -10 mg/dL increase), and higher hemoglobin A_{1c} (OR, 1.23;
39
40 95% CI, 1.13-1.34, per % increase). Similar independent risk factors, except for DBP,
41
42 were found for any retinopathy in patients without MS (Table 6).

43 44 45 46 47 **DISCUSSION**

48
49
50 The data reported population-based information regarding the prevalence of MS and
51
52 its relationship to retinopathy. The overall prevalence of MS was 42.82% using IDF
53
54 criteria; it was a little higher than the study in Beijing.¹⁴ Previous studies reported that
55
56
57
58
59
60

1
2
3
4 the prevalence of the MS was 13.7% in Chinese adult populations. However, the
5
6 prevalence of the MS was 50.0% in Chinese elder populations.^{15,16} It was clear that
7
8 the prevalence of MS was high and might be due to the number of Chinese elder
9
10 increasing and would be representing a problem of public health in social.
11
12 Previous population-based studies in nondiabetic persons have suggested a prevalence
13
14 of retinopathy, ranging from 3.5% to 9%.¹⁷⁻²⁴ It was similar to our outcomes (3.25%).
15
16 However, another study in China had reported that the prevalence of retinopathy
17
18 among participants without diabetes was 13.6%.²⁵ Our study was carried out in urban,
19
20 which may explain partially the lower prevalence found in our study. The overall
21
22 prevalence of retinopathy was 6.36% in total subjects. It was a little higher than the
23
24 results of previous meta-analysis in China.²⁶ In our study, the retinopathy secondary to
25
26 MS and retinopathy secondary to diabetes mellitus were differentiated. Study by
27
28 Keenan *et al.* showed that the prevalence of retinopathy was 8.6% in patients with MS,
29
30 and it was little lower than our results. Similarly, the prevalence of retinopathy (3.6%)
31
32 in patients without MS was a slightly lower than that of this study.²⁴
33
34 To the best of our knowledge, it was the first population-based study provided
35
36 evidence that the relationship between MS and retinopathy in North Chinese
37
38 population, and MS is an independent risk factor of retinopathy after adjusting age,
39
40 gender and other factors. Previously, a community-based study in South China
41
42 (Shanghai) reported that retinopathy were highly associated with accumulated
43
44 metabolic abnormalities.²⁷ In addition, another hospital-based study in China found
45
46 that the prevalence of DR was higher in the MS group.²⁸ Two cross-section studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 have reported the association between the retinopathy and MS in subjects without
5
6 diabetes. The Atherosclerosis Risk in Communities (ARIC) Study revealed a
7
8 relationship between MS and retinopathy in non-diabetic subjects,⁶ whereas in
9
10 another study in Japan, a similar association was found.²⁹ Although the researchers in
11
12 these studies did not reveal the relationship between MS and retinopathy in the
13
14 non-diabetic population, it might be due to this cross-sectional study could not
15
16 prevent itself from being with methodological problems. The study design is
17
18 incapable of estimating causal relation directly. In addition, the results of our study
19
20 proved higher prevalence of retinopathy including PDR in patients with MS.
21
22 Therefore, we could hypothesises that MS as a risk factor for retinopathy in the subjects,
23
24 and more prospective studies are warranted to determine the significance of the MS
25
26 for predicting risk of retinopathy.
27
28

29
30 In this study, we found associations of some individual components of MS with a
31
32 range of retinopathy. After adjusting for age, gender, smoking, drinking and other
33
34 variables, we also found that no matter the presence of MS or not, as defined by the
35
36 IDF guideline, longer diabetes duration, higher systolic blood pressure, higher fasting
37
38 plasma glucose, 2h-postprandial plasma glucose, and higher hemoglobinA_{1c} were the
39
40 independent risk factors for retinopathy. Higher diastolic blood pressure was the
41
42 independent risk factor for retinopathy in patients with MS. HDL levels was not
43
44 associated with the presence of retinopathy lesions, and some early studies also have
45
46 revealed this conclusion.²⁴ According to our results, we also had not found significant
47
48 association between smoking and drinking in patients with or without MS.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 The short coming for this study included it was a population based study in
5
6 community, so there were no fundus fluorescein angiography (FFA), and optical
7
8 coherence tomography (OCT) for assistant diagnosis. The study was conducted only
9
10 in four communities of Shenyang, so there is a selection bias. In addition, we did not
11
12 investigate the type of diabetes for all subjects. So the prevalence of retinopathy in
13
14 diabetes was lower representative.
15
16
17

18 19 CONCLUSION

20
21 In summary, our data demonstrate the presence of MS components is significantly
22
23 associated with the prevalence of retinopathy. Rather, in order to prevent retinopathy
24
25 development, risk factors should be controlled in patients with or without MS. More
26
27 comprehensive studies are needed to clarify the roles of MS and also its relationship
28
29 with retinal vascular disorders.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgement

Thanks to Liaoning Diabetic Eye Center. We thank Sharon Forsyth of the Biomedical Editing International, for help in the language editing of this manuscript.

Contributors: L. L. and S.Y. and J.H.Z. and J.Y.W and J.L. and W.P.T. researched data. D.S.H. and L.L wrote the manuscript and researched data. L.C. and W.P.T. edited the manuscript. L.L. and L.C. and W.P.T. contributed to the discussion. L.L. and D.D.H. wrote the manuscript. All authors have given their final approval of this manuscript.

Funding

This study was funded by National Natural Science Foundation of China (81300783); Liaoning Science and Technology Project (2009225005); Liaoning Department of Health Medical Peak of Construction Project (2010016); Important Platform of Science and Technology for the University in Liaoning Province (16010).

Competing interests: No, there are no competing interests.

Ethics approval: The study was approved by the Ethics Committee of The First Affiliated Hospital Of China Medical University.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

REFERENCES

1. Lakka HM, Laaksonen DE, Lakka TA, *et al.* The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-16.
2. Hoang KC, Le TV, Wong ND. The metabolic syndrome in East Asians. *J Cardiometab Syndr* 2007;2:276-82.
3. Feng Y, Hong X, Li Z, *et al.* Prevalence of metabolic syndrome and its relation to body composition in a Chinese rural population. *Obesity* 2006;14:2089-98.
4. Fang JN, Huang MA, Cui L, *et al.* Investigation on the situation of metabolic syndrome among Han-Chinese and Korean-Chinese in urban of Yanbian area. *Wei Sheng Yan Jiu* 2005;34:759-61.
5. Golden SH, Folsom AR, Coresh J, *et al.* Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002;51:3069-76.
6. Wong TY, Duncan BB, Golden SH, *et al.* Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004;45:2949-54.
7. Soebijanto N, Waspadji S. Adiponectin levels and its role in insulin resistance among adult women with metabolic syndrome. *Acta Med Indones* 2010;42:187-91.
8. Tung TH, Shih HC, Tsai ST, *et al.* A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiol* 2007;14:148-54.

- 1
2
3
4 9. Anan F, Takayuki M, Takahashi N, *et al.* Diabetic retinopathy is associated with
5
6 insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic
7
8 patients. *Hypertens Res* 2009;32:299-305.
9
10
11 10. Zimmet P, Magliano D, Matsuzawa Y, *et al.* The metabolic syndrome: a global
12
13 public health problem and a new definition. *J Atheroscler Thromb* 2005;12:295-300.
14
15
16 11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for
17
18 diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the
19
20 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA),
21
22 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization.
23
24
25
26
27
28
29
30 12. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic
31
32 retinopathy from stereoscopic color fundus photographs--an extension of the modified
33
34 Airlie House classification. ETDRS report number 10. *Ophthalmology*
35
36 1991;98:786-806.
37
38
39
40 13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus
41
42 photographic risk factors for progression of diabetic retinopathy. ETDRS report
43
44 number 12. *Ophthalmology* 1991;98:823-33.
45
46
47
48 14. Li ZY, Xu GB, Xia TA. Prevalence rate of metabolic syndrome and dyslipidemia
49
50 in a large professional population in Beijing. *Atherosclerosis* 2006;184:188-92.
51
52
53 15. Gu D, Reynolds K, Wu X, *et al.* Prevalence of the metabolic syndrome and
54
55 overweight among adults in China. *Lancet* 2005;365:1398-405.
56
57
58
59
60

- 1
2
3
4 16. He Y, Jiang B, Wang J, *et al.* Prevalence of the metabolic syndrome and its
5
6 relation to cardiovascular disease in an elderly Chinese population. *J Am Coll Cardiol*
7
8 2006;47:1588-94.
9
- 10
11 17. Klein R, Klein BE, Moss SE, *et al.* Hypertension and retinopathy, arteriolar
12
13 narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol*
14
15 1994;112:92-8.
16
17
- 18 18. Yu T, Mitchell P, Berry G, *et al.* Retinopathy in older persons without diabetes and
19
20 its relationship to hypertension. *Arch Ophthalmol* 1998;116:83-9.
21
22
- 23 19. Hubbard LD, Brothers RJ, King WN, *et al.* Methods for evaluation of retinal
24
25 microvascular abnormalities associated with hypertension/sclerosis in the
26
27 Atherosclerosis Risk in Communities Study. *Ophthalmology* 1999;106:2269-80.
28
29
- 30 20. Van Leiden HA, Dekker JM, Moll AC, *et al.* BP, lipids, and obesity are associated
31
32 with retinopathy: the Hoorn Study. *Diabetes Care* 2002;25:1320-5.
33
34
- 35 21. Wong TY, Klein R, Sharrett AR, *et al.* The prevalence and risk factors of retinal
36
37 microvascular abnormalities in older persons: the Cardiovascular Health Study.
38
39 *Ophthalmology* 2003;110:658-66.
40
41
- 42 22. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated
43
44 with diabetic retinopathy in the Australian population. *Diabetes Care* 2003;26:1731-7.
45
46
- 47 23. Kawasaki R, Wang JJ, Rochtchina E, *et al.* Cardiovascular risk factors and retinal
48
49 microvascular signs in an adult Japanese population: the Funagata Study.
50
51 *Ophthalmology* 2006;113:1378-84.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 24. Keenan JD, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the
5
6 metabolic syndrome: findings from the Third National Health and Nutrition
7
8 Examination Survey. *Am J Ophthalmol.* 2009;147:934-44, 944.e1-2.
9
10
11 25. Peng XY, Wang FH, Liang YB, *et al.* Retinopathy in persons without diabetes: the
12
13 Handan Eye Study. *Ophthalmology* 2010;117:531-7, 537.e1-2.
14
15
16 26. Liu L, Wu X, Liu L, *et al.* Prevalence of diabetic retinopathy in mainland China: a
17
18 meta-analysis. *PLoS One* 2012;7:e45264.
19
20
21 27. Pang C, Jia L, Hou X, *et al.* The significance of screening for microvascular
22
23 diseases in Chinese community-based subjects with various metabolic abnormalities.
24
25 *PLoS One* 2014;9:e97928.
26
27
28 28. Zhang X, Cui X, Li F, *et al.* Association between diabetes mellitus with metabolic
29
30 syndrome and diabetic microangiopathy. *Exp Ther Med* 2014;8:1867-73.
31
32
33 29. Kawasaki R, Tielsch JM, Wang JJ, *et al.* The metabolic syndrome and retinal
34
35 microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol*
36
37 2008;92:161-6.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic data, selected clinical and laboratory findings in patients with and without MS.

Parameter	With MS(<i>n</i> = 498)	Without MS (<i>n</i> = 665)	<i>p</i> -value
Age (years)	67.1 ±4.2	68.7 ±4.4	0.12
Male (%)	40.2	42.3	0.26
Weight (kg)	74.3 ±12.7	83.4 ±13.6	< 0.001
Height (cm)	168.5 ±10.1	169.3 ±9.7	< 0.001
BMI (kg/m ²)	27.8 ±4.4	30.9 ±4.7	< 0.001
Waist (cm)	94.5 ±9.2	101.4 ±10.3	< 0.001
SBP (mmHg)	124.3 ±12.7	138.4 ±14.2	< 0.001
DBP (mmHg)	78.6 ±9.2	85.0 ±8.6	< 0.001
Triglyceride (mg/dL)	146.4±10.7	176.4±10.3	< 0.001
HDL (mg/dL)	65.2 ±17.4	54.2 ±16.1	< 0.001
FPG (mg/dL)	109.8 ±13.4	97.4 ±11.3	< 0.001
2hPPG (mg/dL)	209.7±11.9	167.1±12.5	< 0.001
HbA _{1c} (% (mmol/mol))	5.4±0.8	7.1 ±1.1	< 0.001
Duration of DM (years)	5.1 ±1.2	8.2 ±1.6	0.01
Smoking (%)	35.6	40.3	0.11
Drinking (%)	39.8	43.3	0.07
Newly detected DM (%)	19.3	24.5	< 0.001

MS: metabolic syndrome; BMI: body mass index; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 2. Retinopathy grade in patients with and without MS.

Retinopathy	With MS (<i>n</i> =48)	Without MS (<i>n</i> =26)
Mild-NPDR	10	9
Moderate-NPDR	11	6
Severe-NPDR	12	6
PDR	15	5

MS: metabolic syndrome; PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy

Table 3. Prevalence of retinopathy in different groups of this study.

Item	Retinopathy (n)	Prevalence (%)
Total diabetes	55	11.79
Known diabetes	34	18.18
Newly detected diabetes	21	7.72
Non-diabetes	19	3.25
With MS	48	9.64
Without MS	26	3.91
Total subjects	74	6.36

MS: metabolic syndrome.

Table 4. Demographic data, selected clinical and laboratory findings in retinopathy patients with nondiabetes.

Parameter	Retinopathy patients with nondiabetes
Age (years)	59.1 ±3.2
Male (%)	44.3
Weight (kg)	75.3 ±11.6
Height (cm)	169.8 ±11.1
BMI (kg/m ²)	28.9 ±5.1
Waist (cm)	95.5 ±8.9
SBP (mmHg)	126.3 ±11.6
DBP (mmHg)	79.5 ±9.1
Triglyceride (mg/dL)	148.5±10.6
HDL (mg/dL)	66.3 ±18.1
FPG (mg/dL)	98.7 ±10.5
2hPPG (mg/dL)	189.8±10.5
HbA _{1c} (% (mmol/mol))	5.2±0.6
Smoking (%)	32.1
Drinking (%)	41.8

BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; SBP: systolic blood pressure; SBP: systolic blood pressure; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 5. Demographic data, selected clinical and laboratory findings in patients with NPDR and PDR.

Parameter	NPDR (n=54)	PDR (n=20)	<i>p</i> -value
Age (years)	68.1 ±4.1	70.7 ±3.4	0.04
Male (%)	45.2	44.6	0.86
Weight (kg)	84.3 ±10.6	85.6 ±11.2	0.54
Height (cm)	166.8 ±11.2	167.7 ±10.7	0.66
BMI (kg/m ²)	26.9 ±4.3	31.1 ±4.2	< 0.001
Waist (cm)	100.6 ±10.2	102.4 ±11.1	0.22
SBP (mmHg)	123.3 ±11.7	132.5 ±12.2	< 0.001
DBP (mmHg)	77.8 ±8.6	84.9 ±7.9	< 0.001
Triglyceride (mg/dL)	145.8±9.7	175.8±11.3	< 0.001
HDL (mg/dL)	64.2 ±16.2	58.6 ±15.1	0.01
FPG (mg/dL)	96.8 ±10.5	108.9 ±12.5	< 0.001
2hPPG (mg/dL)	199.2±11.4	214.8±12.9	< 0.001
HbA _{1c} (% (mmol/mol))	6.7	8.8	< 0.001
Duration of DM (years)	6.1 ±1.3	9.4 ±1.5	0.02
Smoking (%)	40.6	42.4	0.14
Drinking (%)	29.9	31.3	0.11
Newly detected DM (%)	30.2	20.5	< 0.001

PDR: proliferative diabetic retinopathy; NPDR: non-proliferative diabetic retinopathy; BMI: body mass index; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

Table 6. Logistic regression analyses for retinopathy in the population with and without MS.

	With MS				Without MS			
	OR* (95% CI)	p-value	OR# (95% CI)	p-value	OR* (95% CI)	p-value	OR# (95% CI)	p-value
Age (per 10-year)	0.94 (0.78–1.07)	0.39	0.86 (0.58–1.19)	0.11	0.96 (0.74–1.24)	0.70	0.79 (0.41–1.35)	0.22
Gender (female vs male)	0.81 (0.62–1.04)	0.13	0.72 (0.54–1.02)	0.06	1.20 (0.89–1.68)	0.45	1.02 (0.59–1.72)	0.98
BMI (per kg/m ²)	0.97 (0.94–0.99)	0.01	0.98 (0.92–1.06)	0.41	0.96 (0.91–1.00)	0.06	0.99 (0.93–1.04)	0.60
Diabetes duration (per 10-year)	1.06 (1.03–1.10)	<0.001	1.07 (1.04–1.10)	<0.001	1.08 (1.04–1.12)	<0.001	1.07 (1.04–1.10)	<0.001
Weight (per 10-kg)	1.05 (0.71–1.63)	0.79	1.04 (0.62–1.73)	0.88	1.14 (0.52–2.43)	0.74	1.19 (0.44–3.10)	0.74
Height (per 10-cm)	1.43 (0.97–2.06)	0.06	1.31 (0.82–2.09)	0.26	1.69 (0.88–3.26)	0.13	1.31 (0.54–3.18)	0.56
Waist (per 10-cm)	1.34 (0.78–2.32)	0.26	1.32 (0.68–2.57)	0.38	0.98 (0.36–2.52)	0.94	0.67 (0.21–2.28)	0.55
SBP (per 10-mmHg)	1.14 (1.04–1.22)	<0.001	1.16 (1.09–1.29)	<0.001	1.27 (1.14–1.46)	<0.001	1.35 (1.18–1.55)	<0.001
DBP (per 10-mmHg)	1.12 (1.05–1.22)	<0.001	1.24 (1.12–1.35)	0.02	1.15 (1.04–1.28)	<0.001	1.18 (0.97–1.38)	0.66
Triglycerides (per 10-mg/dL)	1.04 (0.88–1.19)	0.66	0.95 (0.78–1.12)	0.49	1.19 (0.94–1.48)	0.14	1.13 (0.86–1.47)	0.39
HDL cholesterol (per 10-mg/dL)	0.87 (0.64–1.18)	0.49	0.77 (0.53–1.12)	0.20	1.03 (0.88–1.22)	0.51	1.13 (0.85–1.44)	0.37
FPG (per 10-mg/dL)	1.06 (1.01–1.11)	<0.001	1.07 (1.02–1.11)	<0.001	1.09 (1.05–1.13)	<0.001	1.11 (1.05–1.17)	<0.001
2hPPG (per 10-mg/dL)	1.16 (1.02–1.32)	<0.001	1.17 (1.12–1.21)	<0.001	1.12 (1.01–1.21)	<0.001	1.13 (1.04–1.22)	<0.001
HbA _{1c} (per % (mmol/mol))	1.25 (1.15–1.35)	<0.001	1.23 (1.13–1.34)	<0.001	1.29 (1.15–1.44)	<0.001	1.26 (1.10–1.44)	<0.001
Current smoker	1.22 (0.87–1.68)	0.39	1.37 (0.79–2.09)	0.47	1.21 (0.68–1.86)	0.59	1.42 (0.68–2.46)	0.44
Current drinker	1.12 (0.57–1.78)	0.33	1.27 (0.68–2.28)	0.65	1.19 (0.58–2.46)	0.59	1.20 (0.55–3.16)	0.55
Newly detected DM	0.89 (0.55–1.26)	0.46	0.78 (0.55–1.23)	0.21	1.00 (0.84–1.32)	0.56	0.96 (0.75–1.33)	0.35

MS: metabolic syndrome; BMI: body mass index; CI: confidence interval; DBP: diastolic blood pressure; HbA_{1c}: hemoglobin A_{1c}; HDL: high-density lipoprotein; OR: odds ratio; SBP: systolic blood pressure; DM: diabetes mellitus; 2hPPG: 2h-postprandial plasma glucose; FPG: fasting plasma glucose.

*Adjusted for age and gender. # Adjusted for age, gender, body mass index, HbA_{1c}, duration of diabetes, SBP and DBP), drinking and smoking.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-8
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.